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Abstract
Kidney transplantation is the treatment of choice for patients with end-stage kidney
disease. However, the shortage of transplantable kidneys has led to ever-increasing waiting
lists. As a result, kidneys obtained via donation after cardiac death (DCD) are being used more
frequently for transplantation. However, they exhibit poorer outcomes due to ischemiareperfusion injury (IRI) and cold preservation methods, such as static cold storage (SCS).
Supplementing cold preservation solutions with hydrogen sulfide donors, such as AP39, has
been shown to improve renal IRI and graft outcomes, but the injury associated with cold
preservation remains. This thesis evaluates the effect of subnormothermic kidney preservation
at 21°C with AP39. In an in vitro model of renal IRI, adding AP39 to University of Wisconsin
(UW) solution improved its viability for subnormothermic preservation at 21°C in a dosedependent manner. Additionally, subnormothermic storage of DCD porcine kidneys in AP39supplemented UW solution reduced necrosis compared to SCS in UW alone. Since oxygenated
perfusion is the norm for normothermic (35-37°C) and subnormothermic (20-34°C) kidney
preservation research, AP39-supplemented autologous blood was used for the ex vivo
perfusion of DCD porcine kidneys at 21°C. The treatment group exhibited higher urine output,
lower tissue injury and pro-survival gene expression patterns compared to subnormothermic
perfusion with blood alone and SCS. Since the use of blood would complicate the clinical
translation of our approach due to national shortages and logistical complexities, we
investigated the effect of adding AP39 to Hemopure, a hemoglobin-based oxygen carrier.
Subnormothermic perfusion of DCD porcine kidneys with AP39-suppelemted Hemopure
improved renal graft function and reduced tissue injury in a similar manner as in the previous
model. Several important conclusions emerged. Adding 200 nM AP39 to preservation
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solutions, blood and blood substitutes improved renal outcomes. Importantly, oxygenated
subnormothermic perfusion with AP39-supplemented perfusates improved DCD kidney
outcomes compared to SCS, the clinical standard of care. Additionally, subnormothermic
preservation with AP39 reduced renal apoptosis and induced pro-survival gene expression.
Overall, we transformed a novel idea into a viable kidney preservation approach that is pending
patent approval. If clinically approved, this approach could facilitate the increased use of DCD
kidneys for kidney transplantation.

Keywords
Hydrogen sulfide, AP39, Kidney Preservation, Subnormothermic, Ischemia Reperfusion
Injury, Apoptosis, Hypoxia, Porcine, Kidney Perfusion, Organ Procurement, Donation after
Cardiac Death, Renal Transplantation.
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Summary for Lay Audience
Kidney transplantation is the treatment of choice for patients with end-stage kidney
disease. However, the shortage of transplantable kidneys has led to ever-increasing waiting
lists. Kidneys from deceased donors are being used more frequently to meet the demand.
Unfortunately, these kidneys typically exhibit poorer outcomes than kidneys from living
donors and thousands of these kidneys are discarded each year due to logistical limitations and
strict selection criteria. As such, strategies that can improve the outcomes and facilitate the use
of more deceased donor kidneys are of interest. One factor that contributes to the poor
outcomes of these kidneys is cold preservation from the time of retrieval until transplantation.
Our research has shown that adding hydrogen sulfide donors to cold preservation solutions
improves kidney graft outcomes. However, the premise of cold preservation still causes tissue
damage. Thus, the aim of this thesis is to evaluate the impact of kidney preservation around
room temperature (21°C) with the use of a hydrogen sulfide donor called AP39. We used a
combination of cellular and pig kidney perfusion models to investigate the effect of adding
AP39 during kidney preservation at 21°C. We found that adding AP39 to preservation
solutions, blood and blood substitutes improved their suitability for kidney preservation at
21°C. Importantly, kidney preservation at 21°C improved renal graft function and reduced
kidney injury compared to cold storage, the clinical standard of care, in our pig kidney
perfusion models. Additionally, AP39 reduced kidney injury and induced pro-survival gene
expression in this context. Overall, we transformed a novel yet obscure idea into a viable and
effective kidney preservation approach that is pending patent approval. If clinically approved
upon testing with discarded human kidneys, this approach could facilitate the increased use of
deceased donor kidneys for kidney transplantation.
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Chapter 1

1

Introduction

Sections 1.6.1 and 1.6.2 have been adapted from:
Juriasingani S, Akbari M, Luke P, Sener A. Novel therapeutic strategies for renal graft
preservation and their potential impact on the future of clinical transplantation. Curr Opin
Organ Transplant. 2019. 24(4):385-390.
Wolters Kluwer Health, Inc ©
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1.1 End-stage renal disease
Chronic kidney disease refers to a persistent and progressive reduction in kidney
function, which is primarily measured using the estimated glomerular filtration rate. This
reduction in kidney function can be caused by a multitude of factors including diabetes,
hypertension and hereditary conditions.1 The final and most severe phase of chronic kidney
disease is referred to as end-stage renal disease (ESRD), where both kidneys have failed
irreversibly and kidney function has decreased to less than 10% of normal. 2 ESRD is a
significant global health concern because no cure exists for this condition. It is estimated
that 1.2 million people died from kidney failure worldwide in 2015, an increase of 32%
since 2005.3 Additionally, the global incidence of ESRD is rising and this trend is evident
in Canada because the number of ESRD patients has increased by 33% between 2010 and
2019.4
ESRD patients require renal replacement therapy to live. The two prevalent forms
of renal replacement therapy are dialysis and kidney transplantation. Dialysis refers to the
mechanical filtration of blood to eliminate waste and toxins in place of the kidneys. In
Canada, 56.8% of ESRD patients were receiving some form of dialysis as of the end of
2019.4 Dialysis takes a toll on patients due to its impact on their quality of life, ability to
work and long-term survival. It also places an enormous burden on the Canadian healthcare
system as the annual cost of dialysis for one patient is nearly $100,000. As a result,
approximately $2.5 billion dollars are spent on the care of Canadians receiving dialysis
each year and this amount increases to $40 billion when considering the costs associated
with CKD broadly.5 While dialysis is the primary treatment modality for ESRD patients in
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Canada, the balance is shifting towards renal transplantation.6 The reasons for this shift are
discussed in the next section.

1.2 Renal Transplantation
Renal transplantation refers to the surgical implantation of a functional donor
kidney into a recipient with kidney failure. In 2019, 1,648 adult kidney transplants were
performed in Canada.7 Between 2010 and 2019, the total number of kidney transplants
performed in Canada has increased by 41%.6 This increase can be attributed to the
superiority of renal transplantation over dialysis in terms of recipient outcomes. A robust
systematic review looking at 110 studies that encompass a total of 1,922,300 patients has
found that most transplant centers report lower mortality, higher 5-year survival rates,
lower risk of cardiovascular events and improved quality of life among transplant
recipients compared to patients on dialysis.8 The Canadian Organ Replacement Register
reports that the unadjusted 5-year graft survival rate is ~ 47% for patients on dialysis
(depending on type of dialysis) vs. ~ 85% for kidney transplant recipients (depending on
type of organ donor).4 Additionally, several studies have shown that transplants are more
cost-effective in the long run than dialysis.9,10 Furthermore, it has been estimated that
increasing the kidney transplant rate in Canada by just 10% could significantly decrease
the burden of CKD on disability payments from public health and pension plans.5

1.2.1 Shortage of organs and increased use of deceased donor
kidneys
One persisting problem that limits the rates of kidney transplantation is the shortage
of donor kidneys that occurs at a regional level across the globe. Despite the 1,648 adult
kidney transplants performed in 2019, 3,261 Canadians were still on the waiting list at the
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end of the year. Additionally, 72 patients died in 2019 while waiting for a kidney
transplant.7 Traditionally, kidneys from living donors (related or unrelated) are preferable
in order to maximize recipient outcomes. However, physicians at many transplant centers
around the world also use marginal/sub-optimal organs from deceased donors to bridge the
gap. Of the 1,648 kidney transplants performed in Canada in 2019, 505 kidneys were
procured from living donors and 1,143 kidneys were procured from deceased donors.7
There are several types of deceased donors and these types have important
implications for post-transplant graft and recipient outcomes. Donation after brain death or
neurologically determined death (DBD or NDD) refers to donors who experienced brain
death but their blood circulation and respiration remained intact by measures such as
ventilation.11 Donation after cardiac death (DCD) refers to donors who experienced a
cardiac standstill or cessation of cardiac function before the organs were procured. DCD
donation can occur as a result of unforeseen tragedies leading to death in a hospital
(uncontrolled DCD) or death resulting from withdrawal of life support (controlled DCD).11
Organs from DCD donors can be considered as marginal because they experience ischemic
injury due to the immediate or gradual reduction in blood flow as cardiac death occurs.
Clinically, DCD kidneys lead to poorer post-transplant outcomes than living donor kidneys
due to the ischemic injury that occurs during cardiac death. DCD and NDD donors can also
be classified as expanded criteria donors (ECD) if they are ≥ 60 years old or aged 50-59
with any two of the following three criteria: (1) death resulting from a stroke, (2) a history
of hypertension, and (3) terminal level of creatinine (a waste product produced by muscles)
in the serum of >1.5 mg/dL.11 Organs from ECD donors, especially ECD/DCD donors, can
also be considered as marginal due to the presence of comorbidities. However, appropriate
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donor and recipient screening can mitigate the risks associated with transplanting organs
from DCD, ECD or ECD/DCD donors.
In an attempt to meet the increasing global demand for kidney transplants, kidneys
from deceased donors are being used more frequently. In Canada, the deceased donor rate
has increased 42% between 2009 and 2018.12 Moreover, the number of organs procured
from DCD donors procured across Canada has increased by 76% between 2015 and 2019.7
However, kidneys from deceased donors are often discarded after being declined for
transplantation due to various reasons including stringent selection criteria and systemic
allocation issues. It is estimated that around 2,700 kidneys are declined annually in the
US.13 Most of these organs are incinerated, but some end up being redirected for research
use. Since these kidneys represent an untapped pool of organs that could help meet the
demand for kidney transplants, strategies that could facilitate their use by mitigating IRI
and improving outcomes are of interest.

1.2.2 Clinical parameters used to evaluate post-transplant graft
function
Renal graft dysfunction is a major clinical concern and several types of
complications can contribute to this condition. Surgical complications include urinary
leaks, renal vascular thrombosis and pseudoaneurysms due to a renal puncture. Medical
complications include graft rejection, drug nephrotoxicity and acute tubular necrosis
(ATN).14,15 Various clinical parameters are used to evaluate post-transplant graft function.
The immediacy, quantity and frequency of urine output are important measures of kidney
function. Additionally, ultrasounds are used to determine the renal resistive index and
detect edema.16 Importantly, blood analysis is critical for determining serum creatinine
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levels and whether a patient is hyperkalemic, acidotic or hypervolemic. Depending on the
patient’s outcomes, dialysis may be required in the first week following the transplant
surgery, which is referred to as delayed graft function (DGF). The exact criteria for the
diagnosis of DGF varies by physician, transplant center, region and country.17 However, it
is undeniable that DGF is a major clinical concern as the incidence of DGF in kidneys from
deceased donors is around 20% across various transplant centers in North America.17
Additionally, DGF leads to decreased long-term graft survival.17,18 Thus, strategies to
mitigate DGF in marginal kidneys are of interest, especially since such organs are being
used more frequently.

1.3 Ischemia-reperfusion injury
One major factor that contributes to DGF is ischemia-reperfusion injury (IRI). IRI
is a result of the interruption in renal blood flow (RBF) that occur as a kidney is procured,
preserved and transplanted. Ischemia refers to the loss of RBF following nephrectomy and
during preservation. This is followed by reperfusion, which refers to the reintroduction of
RBF during transplant surgery. Together, this leads to a series of cellular and physiological
events that damage the kidney graft.19 IRI is an inevitable aspect of kidney transplantation;
however, it is particularly exacerbated in kidneys from deceased donors. For example,
DCD kidneys experience an additional period of ischemia prior to nephrectomy as cardiac
death occurs and blood circulation decreases.20,21 Additionally, kidneys from deceased
donors can experience longer durations of ischemia as they are transported between
transplant centers across the country or continent, which contributes to the increased rates
of DGF observed following the transplantation of these organs.21 Thus, optimizing organ
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preservation and minimizing IRI are critical for reducing DGF and facilitating the
increased use of marginal grafts from deceased donors.
When considering strategies to mitigate IRI, it is important to consider the cellular
mechanisms underlying the clinical manifestations of IRI. Ischemia is characterized by a
cessation of blood flow that results in hypoxia. Hypoxia decreases electron transport chain
activity and causes cells to switch to anaerobic respiration. The resulting decrease in
adenosine triphosphate (ATP) production inhibits the activity of membrane-bound
ATPases, such as the Na+/K+ ATPase,22,23 which causes accumulation of intracellular Na+
followed by an influx of water leading to cellular edema.19 The accumulation of Na+ ions
impairs other transporters, which causes the accumulation of intracellular Ca2+.19 This Ca2+
overload has implications for the mitochondria, which are key sites of IRI-induced
damage.24,25 The accumulation of Ca2+ in the cytoplasm and mitochondrial matrix has been
shown to increase mitochondrial permeability and cause the production of reactive oxygen
species (ROS), both of which are exacerbated during reperfusion.24,26
Prolonged ischemia also causes other mitochondrial events that exacerbate
oxidative damage during reperfusion. Prolonged ischemia can impair the activity of
mitochondrial antioxidant enzymes,27,28 and reduce the activity of the electron transport
chain.29 The subsequent electron leak contributes to an increase in ROS production during
reperfusion. Reperfusion is characterized by the influx of oxygen upon re-establishment of
blood flow, which paradoxically further damages the ischemic tissues rather than reversing
the damage. The leaked electrons reduce the newly present oxygen, which leads to an
excess of superoxide radicals that cannot be cleared by the impaired antioxidant system.24
The ROS that accumulate during reperfusion can damage mitochondrial proteins and
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lipids, which leads to more pronounced impairment of mitochondrial function and eventual
cell death.25 Increased ROS-mediated damage to the electron transport chain leads to more
pronounced ATP depletion, which can cause apoptosis and necrosis.25 ROS-mediated
damage to mitochondrial membrane lipids along with Ca2+-induced mitochondrial swelling
causes the formation of mitochondrial permeability transition pores (MPTP) in the inner
mitochondrial membrane. Additionally, BCL-2-associated X protein (BAX) oligomerizes
and translocates from the cytosol to form pores in the outer mitochondrial membrane. Due
to the increased mitochondrial membrane permeability, cytochrome c is released into the
cytosol where it activates the caspases that carry out apoptosis (Fig. 1-1).24,25,30
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Figure 1-1 Activation of the intrinsic apoptotic pathway during IRI. The accumulation
of Ca2+ and production of ROS causes mitochondrial swelling and impairs mitochondrial
function, which leads to increased mitochondrial permeability. Mediators of the intrinsic
apoptotic pathway, such as cytochrome C, are released which activates caspases that carry
out apoptosis.
In addition to causing oxidative stress and cell death, IRI induces inflammation and
causes microvascular dysfunction, which leads to tissue damage and reduces graft
function.19 Hypoxia-induced endothelial damage reduces the production of vasodilators,
such as nitric oxide, and increases the production of vasoconstrictors, such as endothelin1 and platelet-derived growth factor-B.31,32 Disruption of endothelial cell-cell junctions
causes interstitial edema, which contributes to vascular permeability and reduces RBF.33
In addition, leukocyte adherence and extravasation leads to renal microvascular
congestion, which also decreases RBF, and these processes are facilitated by the
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upregulation of endothelial adhesion molecules during IRI.33 The infiltration of neutrophils
and natural killer cells during reperfusion leads to renal tubular damage and the secretion
of ROS and pro-inflammatory cytokines.19,34,35 Damaged tubular epithelial cells release
danger-associated molecular proteins and contribute to the secretion of pro-inflammatory
cytokines, which potentiates inflammation within the kidney.19,36 In particular, interleukin
6 (IL-6) and tumour necrosis factor-α (TNF-α), are key mediators of kidney injury as they
have been shown to modulate leukocytes and renal tubular cells.36,37 Both of these
cytokines have been linked to acute renal failure in animal models of renal IRI and
knocking down these genes ameliorated renal injury.36,38,39 IRI-mediated microvascular
dysfunction and inflammation are particularly important as they contribute to fibrosis, graft
dysfunction and allograft rejection.19
One of the major pathological consequences of IRI is acute tubular necrosis (ATN),
which can cause DGF in transplant recipients.40–42 Morphologically, ATN manifests as
apoptosis, loss of cells, gaps in the renal tubular architecture and luminal obstruction due
to cell debris. It can be seen throughout the kidney (cortex and medulla) and it is associated
with interstitial damage and endothelial injury.41 Clinically, ATN is linked to a decrease in
glomerular filtration rate, which contributes to DGF.41,42 Another consequence of IRI is
reduced RBF,3343 which also contributes to lower glomerular filtration, and a 40-50%
reduction in RBF has been observed in poorly functioning renal allografts.44 Overall, the
mechanisms underlying IRI are as complicated as the resulting renal graft function and
tissue injury. While the diverse range of effector mechanisms offers a multitude of potential
targets for mitigating renal IRI, it is evident that any therapeutic strategy would need
extensive testing due to the complexity of IRI.

11

1.4 Hypothermic preservation of renal grafts and cold IRI
Optimal organ preservation is essential for mitigating the effects of IRI, especially
with DCD kidneys and marginal grafts. Current organ preservation methods typically
involve hypothermic conditions to lower metabolic demands in order to improve graft
viability in hypoxic storage conditions.45,46 However, prior to the advent of hypothermic
storage, preliminary perfusion pumps and heparinized blood were used to maintain graft
viability and transplants were treated as emergency procedures to minimize graft
injury.45,47 In 1963, Calne et al. conducted one of the earliest investigations into the effect
of cooling kidneys by comparing surface cooling to cooling via perfusion with cold
heparinized blood.48 While the latter method was more effective, the use of cold
heparinized blood caused problems such as reduced RBF in the post-transplant period.
Therefore, the need for acellular organ preservation solutions became apparent.45
Pioneering work by Collins et al. in 1969 led to the development of an acellular
solution (Collins solution) that mimicked intracellular ion concentrations. Canine kidneys
immersed in iced Collins solution were successfully preserved for 30 hours.49 This simple
method of storing kidneys on ice (~4°C) in a preservation solution is referred to as static
cold storage (SCS) and it is the clinical standard of care for kidney preservation across the
globe.45,46 While several preservation solutions have been developed since, University of
Wisconsin (UW) solution and Histidine-Tryptophane–Ketoglutarate solution (HTK) are
two of the frontrunners.50 Their compositions46,50–52 are listed in Table 1. UW solution is
widely accepted as the gold standard cold preservation solution for liver and kidney
preservation.45,46 It mimics intracellular ion concentrations and contains antioxidant and
colloid elements. In comparison, HTK solution has lower potassium levels because it was
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designed for preserving cardiac grafts; however, it has since been found to be effective for
the preservation of abdominal grafts and comparable to UW solution for kidney
preservation.46,50,53
Table 1- The composition of two commonly used kidney preservation solutions.
UW Solution (Bridge to Life ®)

HTK (Custodiol®)

Intracellular

Intracellular, low K+

K+ (mM)

125

10

Na+ (mM)

29

15

Phosphate

Histidine

Lactobionate, Raffinose

Tryptophan,

pentahydrate

α-Ketoglutarate

7.4

7.2

5

5

Glutathione, Allopurinol

Tryptophan

Hydroxyethyl Starch

Mannitol*

Solution Type

Buffer
Cell membrane
stability
pH
Adenosine (mM)
Antioxidant
Colloid

*not a colloid but helps with preventing cellular edema like hydroxyethyl starch
One of the consequences of hypothermic preservation is cold IRI, which has
negative effects on renal graft survival and function.45,54,55 Hypothermia exacerbates the
effects of ischemia by further reducing the activity of the Na+/K+ ATPase, which
contributes to cell swelling.42,49 It also causes a decrease in osmotic pressure that leads to
interstitial edema and preservation solutions try to prevent this with colloid components
like hydroxyethyl starch.47,56,57 To reduce the consequences of cold ischemia, the use of
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dynamic preservation via perfusion pumps re-emerged and hypothermic machine perfusion
(HMP) devices were created. HMP refers to the continuous pulsatile perfusion of the donor
organ with cold preservation solution, which improves the circulation of its components.45
Studies on the benefits of HMP compared to SCS are inconsistent. While some studies
show that HMP can improve renal graft outcomes, others report that it is comparable to
SCS.58–61 However, a growing body of evidence suggests that HMP improves the outcomes
of deceased donor kidneys compared to SCS.62,63 Unfortunately, there are additional
drawbacks to HMP, such as expense and complexity, that limit its use for ex situ organ
procurement.60,64 While both SCS and HMP are approved methods for donor kidney
preservation, these additional factors explain why SCS is used more frequently and is
considered the clinical standard of care.45,58
Importantly, the duration of cold preservation, which is referred to as cold ischemia
time, can significantly impact renal graft outcomes. Several studies have shown that longer
cold ischemia times are strongly associated with DGF, especially in deceased donor kidney
transplants.21,65 A study conducted by Serrano et al. evaluated the outcomes of 81,945
deceased donor kidney transplants in the US and found that longer cold ischemia times
were linked to increased rates of DGF, which led to longer lengths of stay and higher
costs.66 In addition, Debout et al. evaluated the outcomes of 3,829 deceased donor kidney
transplants in France and demonstrated a proportional relationship between each additional
hour of cold ischemia and the risk of graft failure.54 Longer cold ischemia times are
especially detrimental for DCD kidneys. These kidneys experience warm ischemia from
the time when life support is withdrawn until cardiac death, which can take up to 2 hours
or longer, followed by cold ischemia during preservation.67,68 A study by Gill et al. has
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shown that DCD kidneys that experience combinations of warm ischemia times exceeding
48 minutes and cold ischemia times exceeding 48 hours have a higher risk of graft failure.69
Thus, strategies to mitigate the kidney injury that occurs during cold ischemia are of
interest. Many approaches have been investigated, including the use of gasotransmitters to
mitigate cold IRI and kidney preservation at higher temperatures to circumvent cold IRI
altogether.70,71 These approaches are described more thoroughly in subsequent sections.

1.5 The use of exogenous hydrogen sulfide therapy to
mitigate renal IRI
In 1996, a landmark paper by Abe and Kimura reported on the endogenous
production and signaling capability of hydrogen sulfide (H2S).72 This led to its
classification as a gasotransmitter, along with nitric oxide and carbon monoxide. Since then
many groups around the globe have studied its chemical and pathophysiological
effects.73,74 In recent years, the effects of H2S on renal pathophysiology have been studied
in greater detail and exogenous H2S therapy has been shown to mitigate warm and cold
renal IRI.70,75 Emerging evidence suggests that exogenous H2S can protect against IRIinduced oxidative stress, apoptosis, mitochondrial dysfunction, inflammation, and
vasoconstriction, which translates to improved renal graft outcomes.70 Several studies,
including some conducted by our own group, have shown that exogenous H2S can improve
renal graft function and survival using various models of renal IRI and
transplantation.76–80

1.5.1 H2S donors
Considering the low endogenous concentrations of H2S with the body, the
development of physiologically effective H2S donors has been a challenge. Initial studies
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used H2S gas; however, the risk of toxicity and the inability to control H2S concentration
precisely limited its application.73 The most widely used source of H2S are inorganic
sulfide salts like sodium hydrosulfide (NaHS) and sodium sulfide (Na2S). Although they
are referred to as donors, they are solid analogs of H2S gas and they instantly release
H2S.73,74 Several studies, including some by our group, have shown that NaHS can mitigate
renal IRI,79–81 but the immediate H2S release that occurs with the use of NaHS also makes
it difficult to control H2S concentrations precisely.73
Uncontrolled and rapid H2S release can have damaging effects in vivo and it is not
ideal for organ preservation studies. This has led to the development of synthetic H2S
donors like GYY4137 and AP39 that can facilitate slower and more controlled H2S release
upon hydrolysis.74 These compounds have been used successfully in various in vivo models
of disease.77,82 Considering the importance of mitochondrial dysfunction in IRI,24,25
mitochondria-targeted H2S supplementation is of particular interest. Synthetic H2S donor
AP39 is mitochondria-targeted via its positively-charged triphenylphosphonium motif.83,84
It has been shown to support the electron transport chain and cellular bioenergetics at
nanomolar concentrations. Recent studies also report its effectiveness in mitigating cold
myocardial, pancreatic, and renal IRI.77,85,86 The chemical structures of these H2S donors
are shown in Fig. 1-2. Subsequent sections that summarize the protective effects of H2S in
the context of cold IRI will include evidence resulting from the use of these H2S donors.
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Figure 1-2. The chemical structures of commonly used H2S donors.
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1.5.2 H2S protects against oxidative stress
The generation of ROS during IRI causes graft injury. Cold preservation solutions
contain antioxidant components, such as glutathione, to combat ROS. Mechanistically, an
increase in H2S levels reduces ROS production by contributing to the synthesis of
glutathione and by reducing the activity of NADPH oxidase, which is a major source of
ROS production in the kidney.87 Treatment with NaHS has been shown to reduce the
expression of NADPH oxidase 4 in a mouse model of warm renal IRI. The same study also
showed that treatment with NaHS reduced superoxide formation, lipid peroxidation and
the ratio of oxidized glutathione to total glutathione.81 In addition to enhancing antioxidant
defenses by contributing to glutathione synthesis, H2S also increases the expression of
other antioxidant enzymes, such as catalase.81 Using an in vitro model of cold renal IRI,
we have previously shown that treatment of tubular renal epithelial cells with AP39supplemented UW solution reduces ROS levels compared to treatment with UW alone.77
Recent studies have also shown that cold preservation with AP39-supplemented UW
solution reduces ROS levels in in vitro models of myocardial and pancreatic IRI;85,86
however, the exact mechanism underlying this trend remains unknown. It has also been
suggested that H2S interacts with other gasotransmitters (nitric oxide and carbon
monoxide) and cumulative antioxidant effects occur due to their activation of K+ATP
channels.88–90 This effect could be contributing to the findings of the studies discussed
above and more research is needed to determine the exact mechanisms underlying the
antioxidant effects of H2S donors, especially AP39.
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1.5.3 H2S maintains mitochondrial homeostasis and inhibits IRIinduced apoptosis
A growing body of literature shows that H2S inhibits apoptosis in various models
of IRI. Meng et al. have shown that GYY4137 modulates apoptotic gene expression using
in vitro and in vivo models of myocardial IRI.82 They found that treatment with H2S
upregulated B-cell lymphoma-2 (BCL-2), an anti-apoptotic gene, and downregulated
BAX, a pro-apoptotic gene. GYY4137 also reduced the activity of caspase 3, a key effector
enzyme involved in carrying out apoptosis.82 Additionally, our collaborators have shown
that treatment with AP39 reduces apoptosis in their in vitro model of myocardial IRI and
they found that BAX was downregulated in the AP39 group.86 Our results with renal IRI
models align with these findings. Using an in vitro model of cold renal IRI, we have
previously shown that supplementing UW solution with GYY4137 and AP39 improves
tubular epithelial cell viability.77 In addition, we found that SCS of rat kidneys in NaHSsupplemented UW solution reduces renal apoptosis using in vivo models of syngeneic and
allogeneic murine renal transplantation.77,80 Although not yet confirmed, the intrinsic
apoptotic pathway genes implicated as H2S targets in myocardial IRI may also apply to
renal IRI. In addition to modulating the expression of genes of this pathway, H2S donors
(including AP39) can reduce cytochrome c, which suppresses sulfide signaling (through
persulfidation) and, subsequently, the pro-apoptotic activity of caspase 9.91
One interesting aspect of our previous in vitro results was that nanomolar
concentrations of mitochondria-targeted H2S donor AP39 were 1000-fold more potent in
preserving cell viability than similar concentrations of GYY4137.77 Since the mitochondria
are well established as key sites of IRI, it is important to consider the impact of H 2S on
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mitochondrial homeostasis. Several studies have reported that AP39 preserves
mitochondrial membrane potential, which prevents the formation of the mitochondrial
permeability transition pore that initiates apoptosis.77,86 Another possible mechanism that
may be contributing to the enhanced anti-apoptotic effect of mitochondria-targeted H2S is
its effect on the oxidative phosphorylation machinery. During ischemia, a lack of blood
flow causes lower oxygen delivery to the tissues, which impairs this machinery and results
in ATP depletion.22 ATP depletion has been shown to cause apoptosis and necrosis in
murine proximal tubular cells.92 The effects of H2S on metabolism are complicated. At
high concentrations, H2S can inhibit complex IV and this inhibition is thought to be the
mechanism underlying the hypometabolic states induced by H2S.93 However, H2S also has
the ability to maintain metabolism by acting as an electron donor. Electron donation to the
ETC maintains ATP synthesis, which promotes cell survival at a local level and improves
graft function at a systemic level. Szczesny et al. have shown that low concentrations of
AP39 (30-100nM) stimulate the ETC in endothelial cells subjected to oxidative stress while
high concentrations (300nM or greater) have an inhibitory effect.83 In summary, exogenous
H2S donors, especially mitochondria-targeted donor AP39, can reduce tissue injury and
increase viability during IRI by controlling the expression of apoptotic genes and by
maintaining mitochondrial homeostasis.

1.5.4 H2S counteracts IRI-induced vasoconstriction
One of the factors that contributes to renal IRI and DGF after transplantation is
vasoconstriction. Cold preservation of kidneys has been shown to cause a time-dependent
increase in renal vasoconstriction by upregulating the expression of renal endothelin-1.94
Recent evidence suggests that H2S can counteract the effects of vasoconstriction by
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inducing vasodilation. Xia et al. have reported an increase in RBF and glomerular filtration
rate after the infusion of NaHS into the intrarenal arteries of rats.95 Using an in vivo porcine
model of DCD renal transplantation, we have previously shown that HMP with NaHSsupplemented UW solution improves RBF and reduces intrarenal resistance compared to
HMP with UW alone.96 From a mechanistic standpoint, the H2S-mediated increase in RBF
is not fully understood. However, a study evaluating the effect of NaHS in a myocardial
IRI model suggests that the activation of K+ATP channels contributes to this effect, which
could be applicable to the kidney as the blockade of these channels contributes to renal IRI.
97,98

It is interesting to note that cyclosporine, an immunosuppressive agent that is widely

used after renal transplantation, also contributes to vasoconstriction. Its nephrotoxic effects
include interstitial fibrosis and renal atrophy.99 A recent study has shown that infusion of
Na2S during the reperfusion of porcine kidneys after 2 hours of cold preservation improved
urine output and RBF, indicating a reversal of the vasoconstriction and glomerular atrophy
caused by cyclosporine.100 Overall, these studies show that H2S-induced vasodilation can
reverse IRI-induced and drug-induced vasoconstriction during in the acute post-transplant
period along with increasing RBF and reducing renal resistance.

1.5.5 H2S suppresses IRI-induced inflammation
In addition to its antioxidant, anti-apoptotic and vasodilatory effects, recent studies
suggest that H2S suppresses inflammatory responses in various disease models. Early work
by our group showed that prolonged SCS of rat kidneys in NaHS-supplemented UW
solution improved post-transplant outcomes (serum creatinine, urine output and survival)
vs. UW solution alone.80 Importantly, treatment with NaHS reduced the infiltration of
leukocytes (macrophages and neutrophils) and the expression of pro-inflammatory
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cytokines, such as interferon-gamma.80 Ahmad et al. have shown that AP39 reduced
neutrophil infiltration in a renal IRI model in rats. 76 The exact mechanism underlying the
anti-inflammatory effects of H2S in renal IRI has not been elucidated. However, the
findings described above are supported by studies that have evaluated the use of H2S
donors in other disease models. In a study on the effects of H2S on rat cardiomyocytes
infected with Coxsackie virus B3, it was found that GYY4137 inhibits the expression of
the following pro-inflammatory cytokines: TNF-α, interleukin-1β (IL-1β) and IL-6.101
Additionally, both GYY4137 and AP39 have been shown to inhibit the expression of TNFα and IL-6 in the context of airway hyperreactivity.102 Furthermore, AP39 attenuated the
increase of TNF-α and IL-6 in a mouse model of burn injury.103 Interestingly, our
collaborators have reported that SCS of murine heart grafts in AP39-supplemented UW
solution protects heart graft function using an in vivo model of heterotopic heart
transplantation. In addition, treatment with AP39 reduced the expression of TNF-α, IL-1β
and IL-6 and increased cell viability in their in vitro model of cold myocardial IRI.86 These
studies on AP39 have been published fairly recently and there is still plenty to discover.
While research on the anti-inflammatory effects of H2S in the kidney is in its early stages,
the literature suggests that H2S donors like AP39 can suppress key inflammatory mediators
of renal IRI.
In summary, H2S confers protection against renal IRI by causing vasodilation,
reducing inflammation, preventing apoptosis, and minimizing oxidative stress.
Additionally, supplementing cold preservation solutions, such as UW solution, with
exogenous H2S donors shows potential as a novel therapeutic strategy to minimize cold
IRI-induced damage.
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1.6 Alternatives to cold preservation
(Sections 1.6.1 and 1.6.2 have been adapted from Juriasingani et al.71)
While improvements to cold preservation methods, such as exogenous H2S therapy
can improve renal graft outcomes, the context of cold IRI and the damage associated with
it would still be present. Longer cold ischemia times increase the incidence of DGF,
especially for marginal kidneys.104 Thus, research evaluating alternatives to cold
preservation that use temperatures closer to 37°C has gained momentum.

1.6.1 Normothermic preservation
The alternative to cold preservation that has been studied the most is normothermic
machine perfusion (NMP), which refers to the oxygenated ex vivo perfusion of kidneys at
37°C. Hosgood et al. (UK) and Selzner et al. (Canada) have led critical research efforts to
establish this approach. Both groups utilize erythrocyte-based, leukocyte-depleted
perfusates that were supplemented with various additives for the duration of NMP.105,106
Hosgood et al. have shown that NMP after SCS or HMP improves ex vivo graft outcomes
using a porcine DCD kidney perfusion model.105,107 In 2011, they performed the first in
man renal transplantation where, using paired kidneys, they showed that 30 min of NMP
after SCS improved post-transplant outcomes compared to SCS only.108 Since then, they
have developed a quality scoring system based on studies evaluating NMP using declined
human kidneys. In 2018, they validated this system by transplanting human kidneys based
on their quality scores.109–111 Currently, they are leading an ongoing phase II clinical trial
to evaluate the effectiveness of transplanting DCD kidneys after NMP vs. SCS. 112,113 In
North America, Selzner et al. have compared prolonged NMP to prolonged SCS along with
several combinations of NMP after SCS.106,114,115 They have shown that prolonged NMP
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(16 hours) improves outcomes compared to prolonged SCS and brief durations of NMP
after SCS.115 They are currently leading a phase I clinical trial to evaluate the feasibility of
NMP using their perfusate and perfusion apparatus.116
Several exogenous therapies have also been shown to improve renal graft outcomes
in the normothermic setting. These studies administer compounds prior to or during ex vivo
reperfusion with blood, which can be seen as analogous to NMP since both involve kidney
perfusion at 37°C. It has been shown that supplementing autologous blood with siRNA
targeting caspase 3 during ex vivo reperfusion reduced apoptosis along with improving
RBF and O2 consumption.117 Additionally, administering NaHS intravenously 10 mins
prior to and after the start of ex vivo reperfusion improved RBF and the function of DCD
pig kidneys.118 Thus, in addition to eliminating the ill effects of cold IRI, the use of NMP
could facilitate the circulation of promising therapeutics within kidney grafts to further
improve their outcomes. Overall, the recent interest in NMP reflects a major shift in the
field of kidney preservation. However, this technique has not yet been approved for clinical
use and several barriers (discussed in section 1.6.3) need to be overcome before it can be
implemented clinically.

1.6.2 Subnormothermic preservation
Due to the interest in NMP and improving HMP, questions about whether
subnormothermic temperatures (20-34°C) may be beneficial for preserving renal grafts
remain unanswered. The interest in subnormothermic preservation stems from the idea that
cold IRI can be prevented at these temperatures without raising metabolic demand to
physiological levels, as is the case with normothermic preservation. Very few studies have
evaluated the impact of subnormothermic perfusion on kidney outcomes compared to SCS
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and HMP. In the early 2000s, a group based in the Netherlands showed that a period of
perfusion at 32-34°C with metabolic support following prolonged SCS improved the
outcomes of pig and declined human kidneys.119–121 However, this approach was never
directly compared to SCS and the research was later abandoned. In 2014, Hoyer et al.
compared the effects of SCS, oxygenated HMP and oxygenated subnormothermic
perfusion at 20°C on DCD porcine kidney outcomes. Subnormothermic kidney perfusion
with a modified version of HTK solution at 20°C led to higher blood flow, urine output
and creatinine clearance than SCS and HMP during reperfusion with autologous blood.122
Since established preservation solutions appear to work at ~20°C, it is possible that
supplementing these solutions with H2S and other exogenous therapies may improve renal
outcomes during subnormothermic preservation at ~20°C like it does with SCS. As is the
case with normothermic preservation, subnormothermic preservation has not been
approved for clinical use yet and several barriers (discussed in section 1.6.3) need to be
overcome before it can be implemented clinically.

1.6.3 Challenges with the clinical translation of these approaches
The clinical implementation of normothermic and subnormothermic perfusion is
limited by several factors. One key factor is the lack of a standardized perfusion protocol.
The literature on this subject reports the efficacy of various temperatures with the use of
diverse perfusates, including blood-based, erythrocyte-based and acellular solutions.115,122–
124

Additionally, diverse additives ranging from colloids and nutrients to antibiotics and

anticoagulants have been used to optimize kidney graft outcomes in these studies.123 Since
a multitude of temperatures and perfusates have been effective, the development of a
standardized clinical protocol is difficult and the use of whole blood or red blood cells in
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the literature further complicates matters (discussed in section 1.6.4).123 Another limiting
factor is the lack of an approved portable perfusion apparatus that can support these
approaches during ex situ organ procurement. Existing HMP devices are built to circulate
acellular solutions and maintain cold conditions (4°C). In their current form, these devices
do not support higher temperatures, oxygenation, the circulation of blood, the addition of
nutrients and the collection of samples (perfusate and urine). The lack of industry support
and the focus on improving HMP strategies has delayed the development of perfusion
devices that support normothermic and subnormothermic kidney perfusion.123 Since
kidneys can tolerate prolonged cold ischemia and dialysis can be used in cases of DGF,
there is little incentive to shift away from HMP and invest in novel technologies.123
However, strategies that facilitate the use of marginal grafts are critical for increasing
transplant rates and it is clear that SCS and HMP are not ideal methods for preserving these
grafts. Cost is an additional limiting factor in this context. The clinical trials and
technological advancements needed to facilitate the clinical implementation of
normothermic and subnormothermic kidney perfusion require significant monetary
resources.123 From an industry standpoint, investing in these approaches may not seem
advantageous until it is evident that they lead to a significant improvement of kidney
outcomes compared to HMP.123 However, the development of clinical normothermic and
subnormothermic kidney preservation protocols is essential for facilitating the assessment,
preservation and transplantation of marginal kidneys.

1.6.4 The use of blood substitutes in kidney preservation
The potential use of red blood cells and whole blood for normothermic and
subnormothermic kidney preservation complicates the clinical translation of these
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approaches. While banked red blood cells are readily available, their use after longer
banking times can lead to inflammation and hemolysis.123 Meanwhile, the presence of
leukocytes and platelets in whole blood can lead to thrombosis and amplify IRI through
endothelial activation and neutrophil infiltration.123,125 The use of plasma, following the
depletion of leukocytes and platelets, can help maintain osmotic pressure but the risk of
thrombosis remains due to the presence of fibrinogen.123 Paradoxically, the large doses of
heparin that are being used to prevent thrombosis can cause the aggregation of red blood
cells.123 From a logistical standpoint, regional shortages of blood and the unreliability of
blood collection from DCD donors (blood loss due to trauma/gradual cessation of blood
flow) limit the availability and use of blood or plasma for kidney preservation.
Additionally, the timely screening and cross-matching of blood to ensure its compatibility
to the graft could be challenging, especially considering the unpredictability of DCD
kidney procurement. Furthermore, existing portable perfusion devices are designed for the
use of acellular solutions that are less viscous than blood. Thus, acellular oxygen-carrying
perfusates are of interest in order to circumvent the challenges described above and meet
the increased metabolic demand that occurs during kidney preservation outside of cold
conditions.46,123
Blood substitutes, such as hemoglobin-based oxygen carriers, have been used in the
literature to replace the use of blood in kidney preservation protocols. In the early 2000s,
Brasile et al. used pyridoxilated bovine hemoglobin in their exsanguinous metabolic
support solution, which was used to perfuse porcine and declined human kidneys at 3234°C.119–121 Since then, Hemopure (Hemoglobin-based oxygen carrier- 201, HbO2
Therapeutics LLC) has emerged as a promising candidate for kidney perfusion. Hemopure
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is an acellular solution of polymerized bovine hemoglobin.126,127 It is similar to human
hemoglobin in terms of its oxygen carrying capacity and it releases oxygen more readily.128
Additionally, it is stable for a long period of time at a wide range of temperatures (3 years,
3–30°C).126 Using declined human kidneys, Aburawi et al. have reported that 6 hours of
NMP with Hemopure vs. packed red blood cells leads to comparable kidney outcomes.129
A recent study by our centre has shown that 4 hours of subnormothermic perfusion at 22°C
with Hemopure reduced DCD pig kidney injury compared to SCS.130 Additionally,
subnormothermic perfusion with Hemopure vs. autologous blood led to equivalent oxygen
saturation, RBF, graft function and urinary damage markers. Thus, Hemopure is a
promising alternative to blood in the context of subnormothermic kidney perfusion.

1.7 Rationale and Objectives

1.7.1 Rationale
Renal transplantation is the treatment of choice for patients with ESRD.4 However,
the demand for kidney transplants exceeds the supply of donor kidneys.7 Renal grafts from
deceased donors are being used more frequently to meet the demand.12 However, these
kidneys exhibit higher rates of DGF and their long-term graft survival is lower than kidneys
procured from living donors.17,18 Despite these measures, 3,261 Canadians were still on
the waiting list at the end of 2019 and 72 patients died during that year while waiting for a
kidney transplant.7 Additionally, some transplant recipients require more than one
transplant within their lifetime due to the limited lifespan of kidney grafts as approximately
10% of all the kidney transplants performed in Canada between 2004 and 2013 were re-
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transplants.131 Furthermore, several thousand deceased donor kidneys are discarded each
year in North America due to stringent selection criteria and logistical factors.13 Taken
together, these factors indicate the need for novel strategies than enhance graft longevity
and facilitate the use of more marginal kidneys to increase transplant rates.
One of the major barriers limiting the attainment of these goals is IRI, an inherent
consequence of the blood flow interruptions that occur during the transplantation process.19
IRI contributes to DGF and lower graft survival.40–42 DCD kidneys experience particularly
severe IRI due to the warm ischemic injury that occurs as a consequence of cardiac death.69
Organ preservation is a key phase of the transplantation process in terms of mitigating IRI.
Current preservation methods rely on the use of cold conditions (4°C) and acellular
solutions.64 However, the resulting cold ischemia is linked to poorer post-transplant
outcomes.65 Thus, there is growing interest in alternative preservation approaches that can
eliminate the ill effects of cold IRI. Recent research suggests that organ preservation at
normothermic and subnormothermic temperatures is preferable, particularly for DCD
kidneys, but there is no consensus on an optimal temperature or protocol.71
Supplementing UW solution with exogenous H2S donors, particularly AP39, has
been shown to improve renal graft outcomes following prolonged periods of static cold
storage.77,79,80 These improvements can be attributed to the diverse protective effects of
administering low concentrations of H2S.70 Seeing cold preservation solutions are effective
for subnormothermic kidney preservation at ~20°C,122 the effect of H2S supplementation
in this context is of interest. Additionally, since the research on normothermic and
subnormothermic preservation routinely employs oxygenated perfusion with blood and
other oxygen-carrying perfusates,123 the effect of adding of H2S to these protocols is also
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of interest. The primary objective of my thesis was to evaluate the effect of
subnormothermic preservation at 21°C with AP39 on DCD renal outcomes compared to
static cold storage, the clinical standard of care. Cutting edge in vitro and ex vivo models
were used to sequentially investigate the effect of adding AP39 to UW solution, blood and
Hemopure during subnormothermic preservation. Through this approach, I sought to
establish a novel kidney preservation method that is feasible for clinical translation by
using established pre-clinical porcine models and considering anticipated obstacles, such
as the complexities associated with using blood.

1.7.2 Objectives
Objective 1. Evaluate the effectiveness of AP39-supplemented UW solution for static
subnormothermic storage at 21°C using an in vitro model of renal IRI and an ex vivo model
of DCD porcine renal graft preservation.
Objective 2. Investigate whether ex vivo subnormothermic perfusion at 21°C with AP39supplemented blood improves DCD porcine renal graft outcomes compared to static cold
storage.
Objective 3. Using a novel blood-free model of preservation and reperfusion, investigate
whether ex vivo subnormothermic perfusion at 21°C with AP39-supplemented Hemopure
improves DCD porcine renal graft outcomes compared to static cold storage.
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2.1 Abstract
Renal transplantation is the preferred treatment for end-stage renal disease.
Currently, there is a large gap between the supply and demand for transplantable kidneys.
The use of sub-optimal grafts obtained via donation after cardiac death (DCD) is on the
rise. While static cold storage (SCS) in University of Wisconsin (UW) solution on ice (4°C)
is the clinical standard of care for renal graft preservation, cold storage has been associated
with negative graft outcomes. The alternative, normothermic machine perfusion, involves
mechanical perfusion of the organ at physiological or normothermic temperature (37°C)
and this technique is expensive, complicated and globally inaccessible. As such, simpler
alternatives are of interest. Preliminary results revealed that UW solution is more protective
at 21°C than 37°C and subnormothermic preservation is of interest because it may facilitate
the use of existing solutions while preventing cold injury. We have previously shown that
SCS in UW solution supplemented with mitochondria-targeted H2S donor AP39 improves
renal graft outcomes. As such, it was hypothesized subnormothermic preservation at 21°C
with AP39 will also improve renal outcomes. Using an in vitro model of hypoxia and
reoxygenation, we found that treating porcine tubular epithelial cells with UW+5uM AP39
during 18h hypoxia at 21°C significantly increased renal tubular epithelial cell viability
after 24h of reoxygenation at 37°C compared to UW alone. Also, AP39-supplemented UW
solution was significantly more cytoprotective during hypoxia at 21°C than hypoxia at
37°C, regardless of AP39 concentration. Using an ex vivo DCD organ preservation model,
we found that DCD porcine kidneys stored for 24h in UW+200nM AP39 at 21°C showed
significantly lower tissue necrosis than DCD porcine kidneys preserved using SCS in UW
solution, the clinical standard of care. Overall, our findings suggest that exogenous H2S
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supplementation improves the viability of the gold standard organ preservation solution,
UW solution, for subnormothermic preservation at 21°C.

2.2 Introduction
Renal transplantation is the treatment of choice for patients with end-stage renal
disease. Several studies have shown that renal transplantation is superior to dialysis in
terms of long-term survival outcomes, quality of life and cost-effectiveness [1–3]. The
global incidence of end-stage renal disease is on the rise and there is a limited supply of
donor kidneys that are suitable for transplantation. This has led to an ever-increasing
number of patients on transplant waitlists. Organs from living donors are preferred for
optimal transplant outcomes. However, sub-optimal grafts from donation after cardiac
death (DCD) donors are being used more frequently to bridge the gap between the supply
and demand for transplantable kidneys [4,5]. One of the factors that influences transplant
outcomes and contributes to the preference for living donors is ischemia-reperfusion injury
(IRI). IRI is an inevitable consequence of the loss and subsequent gain of blood flow during
transplantation. Delayed graft function (DGF) is an important consequence of IRI that is
strongly linked to acute graft rejection and early graft loss [6]. IRI is an especially important
factor to consider with DCD kidneys because they experience prolonged warm ischemia
upon withdrawal of life support until cardiac arrest, which leads to increased rates of DGF
[4]. Considering the increase in end-stage renal disease and the demand for transplantable
kidneys, strategies to mitigate renal IRI are of interest in order to maximize renal graft
survival and expand the pool of donors.
When considering strategies to mitigate IRI, it is important to consider the cellular
mechanisms underlying the clinical manifestations of IRI. Ischemia is characterized by a
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cessation of blood flow that results in hypoxia. Hypoxia decreases electron transport chain
(ETC) activity and causes cells to switch to anaerobic respiration. The resulting decrease
in ATP production inhibits the activity of membrane-bound ATPases, such as the Na+/K+
ATPase [7,8]. The accumulation of Na+ ions impairs other transporters, which causes the
accumulation of intracellular Ca2+ [9]. The accumulation of Ca2+ in the cytoplasm and,
eventually, the mitochondrial matrix has been shown to increase mitochondrial
permeability and cause the production of reactive oxygen species (ROS), both of which are
exacerbated during reperfusion [10–12]. Reperfusion is characterized by the influx of
oxygen upon re-establishment of blood flow, which paradoxically further damages
ischemic tissues instead of reversing the ischemic damage. The leaked electrons, due to
impaired ETC activity, reduce the newly present oxygen, which leads to an excess of ROS
that cannot be cleared [10,13–15]. ROS-mediated damage to ETC complexes leads to more
pronounced ATP depletion, which can cause cell death [12]. ROS also damage
mitochondrial membrane lipids which, along with Ca2+-induced mitochondrial swelling,
causes the opening of mitochondrial permeability transition pores (MPTPs). Due to the
increased mitochondrial membrane permeability, mediators of the intrinsic apoptotic
pathway are released into the cytoplasm, which initiates apoptosis [10, 11]. Thus, the
cellular mechanisms underlying IRI are complicated.
Optimal preservation of the donor organ prior to transplantation is essential for
mitigating the effects of IRI, especially for sub-optimal DCD grafts. The current clinical
standard of care for renal graft preservation is static cold storage (SCS) in University of
Wisconsin (UW) solution on ice at 4°C [16]. However, the resulting cold IRI has been
linked to increased risk of DGF, graft failure and patient death along with reduced long-
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term graft survival [16–18]. To limit these negative effects, hypothermic machine perfusion
(HMP), where the donor organ is continuously perfused with preservation solution, was
introduced [16]. While the increased distribution of nutrients and the clearance of toxic
metabolites with HMP are perceived benefits, studies comparing HMP to SCS are
inconsistent [19–22]. There are additional drawbacks to HMP, such as expense and
complexity, that make this approach less feasible than SCS [21,23]. Since donor organs are
routinely preserved in cold conditions until the time of transplantation, the repercussions
of cold IRI are an important concern in most renal transplantation cases, especially those
involving DCD grafts due to the prior warm ischemic injury as cardiac death occurs. As a
result, novel organ preservation strategies are of interest to circumvent the damage caused
by cold IRI.
An emerging strategy with therapeutic potential against IRI is exogenous hydrogen
sulfide (H2S) therapy. H2S is an endogenously produced gasotransmitter with diverse
cytoprotective effects. Recent studies, including some conducted by our own group, have
shown that H2S therapy can mitigate oxidative stress, inflammation, apoptosis and
mitochondrial dysfunction caused by IRI [24–27]. Using rat models of syngeneic and
allogeneic renal transplantation, we have previously shown that prolonged SCS in NaHSsupplemented UW solution can improve post-transplant graft survival and function
[25,26]. However, the immediate and robust release of H2S caused by inorganic sulfide
salts like NaHS upon suspension makes it difficult to control H2S concentrations precisely
[28]. This has led to the development of synthetic, slow-releasing H2S donors. AP39 is a
synthetic H2S donor that is also mitochondria-targeted via its triphenylphosphonium motif
[29]. Using a rat model of syngeneic renal transplantation, we have previously shown that
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prolonged SCS in AP39-supplemented UW solution improves post-transplant graft
outcomes [27]. Additionally, using an in vitro model of renal IRI, it was found that AP39
is 1000-fold more cytoprotective than non-targeting H2S donors [27]. Thus, cold storage
of renal grafts in H2S-supplemented preservation solutions can improve outcomes,
however, the premise of cold IRI remains.
To prevent the negative effects of cold IRI altogether, organ preservation at
temperatures closer to physiological temperature (37°C) is of interest. The existing
technique is normothermic machine perfusion (NMP) where the organ is perfused with
oxygenated autologous blood, erythrocyte-based solutions or acellular solutions at 37°C
[30]. Several studies have shown that NMP improves renal graft outcomes compared to
SCS [31–35]. Additionally, subnormothermic machine perfusion (SMP) of DCD porcine
grafts at 20°C has been shown to improve graft outcomes compared to HMP and SCS [36].
However, the challenges of NMP and SMP include technical complexity, economic
viability, and logistical problems as no standard perfusion apparatus or protocol exists.
Additionally, these approaches are not very suitable for ex situ organ procurement [23].
Due to these challenges, simpler alternatives are of interest. One possible approach is a
subnormothermic equivalent of SCS. Therefore, this study aims to investigate the
effectiveness of H2S-supplemented UW solution for static subnormothermic preservation
using an in vitro model of renal IRI and an ex vivo porcine model of DCD renal graft
preservation.
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2.3 Materials and Methods
In vitro model of renal IRI
An in vitro model of renal ischemia-reperfusion injury (Fig. 2-1) was used to
investigate the protective effects of AP39-supplemented UW solution during hypoxic
storage at 10°C, 21°C and 37°C.

Figure 2-1 In vitro model of renal IRI. A summary of the in vitro renal IRI model used
to analyze the protective effects of AP39-supplemented UW solution during cold,
subnormothermic and normothermic organ preservation.
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Cell culture
LLC-PK1 cells (ATCC, USA), proximal tubular epithelial cells from porcine
kidneys, were used in the in vitro experiments because proximal tubule cells are susceptible
to ischemic injury [37]. Porcine kidney cells were also used for consistency with the pig
organ preservation model used for the second aim of this study. The cells were cultured in
75cm2 flasks using 10mL of Media 199 containing 10% fetal bovine serum (FBS)
inactivated by heat at 60°C for 30 minutes and 1% penicillin/streptomycin (P/S). The cells
were incubated at normal growth conditions of 37°C, 5% CO2, and 21% O2. At ~80-90%
confluence, 0.25% trypsin-EDTA was used to passage or split the cells for experiments.
All cells used were below the 20th passage. All supplies, except the cells, were purchased
from Thermo Fisher Scientific, USA.
Cell preparation for experiments
LLC-PK1 cells were seeded in 6-well plates (4x105 cells/well). Once the cells were
~80-90% confluent in Media 199 (10% FBS, 1% P/S), the media was aspirated and
phosphate-buffered saline (PBS) was used to wash the cells. Cells were then assigned to
experimental treatments.
Experimental conditions and treatments
A 1mM stock solution of AP39 was made by suspending AP39 (provided by Dr.
Matt Whiteman) in 100% (v/v) dimethyl sulfoxide (DMSO) (AMRESCO Inc, USA). The
1mM stock solution of AP39 was then diluted in Belzer UW® Cold Storage Solution
(Bridge to Life, USA) to make the following six treatment groups: UW only and UW
supplemented with 5nM, 50nM, 500nM, 5µM or 10µM AP39. UW solution was used
instead of media because UW solution is clinically used for organ preservation. All
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treatments were normalized to contain 0.5% (v/v) DMSO to control for any cell death
caused by DMSO. The treatments were applied in duplicate to the LLC-PK1 cells in the 6well plates by adding 1mL of treatment per well. Negative control cells were treated with
UW solution with 0.5% DMSO. The plates were then incubated at 10°C, 21°C or 37°C for
18h in hypoxic growth conditions (4% CO2, 0.5% O2, 95% N2) to simulate ischemia during
cold, subnormothermic and normothermic organ preservation conditions. These conditions
were created using a HypOxystation® H85 hypoxia chamber (HYPO2XYGEN, USA).
Following hypoxia, the treatment solutions were aspirated and 2mL of Media 199 (10%
FBS, 1%P/S) was added to each well. The plates were reoxygenation via incubation in
normoxic growth conditions (37°C, 5% CO2, 21% O2) for 24h to simulate reperfusion and
associated injury. Positive control cells were grown in 6-well plates in normoxic growth
conditions (37°C, 5% CO2, 21% O2) in Media 199 (10% FBS, 1%P/S) for the 18h hypoxia
period and the 24h reoxygenation period.
Analysis of cellular viability, apoptosis and necrosis
The cells samples were analyzed for viability, apoptosis and necrosis after
reoxygenation. The reoxygenation media was collected in labeled flow tubes. Each well
was washed with 2mL of 1X PBS to remove any traces of FBS. Subsequently, 500µL of
0.25% trypsin-EDTA was added to each well and the plates were incubated at 37°C for 36 minutes to accelerate the detachment of the monolayer of cells. Following incubation,
500µL of Media 199 (10% FBS, 1%P/S) was added to each well to inactivate the trypsin
and the media containing the detached cells was collected and added to the labeled flow
tubes. The flow tubes were pelleted via centrifugation (600 x g for 6 minutes) and then
resuspended in 1X PBS followed by identical centrifugation. The cells were then
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resuspended in 250µL of 1X Annexin-V Binding Buffer (BioLegend, USA). Following
resuspension, 2µL of FITC-conjugated Annexin-V (FITC-Annexin-V) (BioLegend, USA)
and 4µL of 7-Aminoactinomycin D (7-AAD) (BioLegend, USA) were added to each
sample to stain for apoptosis and necrosis respectively. In order to optimize detection, all
samples were incubated in the dark for 15 minutes. The stained samples were then analyzed
for cell viability, apoptosis, and necrosis using the CytoFLEX S (Beckman Coulter, USA).
One sample of unstained live cells and two samples of heat-killed cells (90°C, 12 minutes),
stained with either FITC-Annexin-V or 7-AAD, were used for compensation. FlowJo® V10
(FlowJo LLC, USA) was used to appropriately gate the data for statistical analysis.
Data analysis
All statistical analyses were conducted using GraphPad Prism Version 7. For results
obtained from one set of hypoxia and reoxygenation experiments (10°C, 21°C or 37°C
hypoxia), one-way analysis of variance (ANOVA) and Tukey’s post-hoc test were
performed to determine the statistical differences between multiple treatment groups. To
compare the results of all treatment groups between two different sets of hypoxia and
reoxygenation experiments (21°C hypoxia vs. 37°C hypoxia or 10°C hypoxia vs. 21°C
hypoxia), multiple t-tests with the Holm-Sidak method for multiple comparisons were
performed. Statistical significance was accepted at p<0.05.
Subnormothermic temperature and H2S donor selection
Prior to the conditions used with the in vitro model in this study, preliminary
experiments were performed to test the protective effects of UW solution at various
temperatures and to test the cytoprotective effects of adding two different H2S donors to
UW solution. The novel subnormothermic temperature (21°C) was selected based on
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preliminary data which showed that UW solution was more cytoprotective during 12h of
subnormothermic hypoxia at 21°C than normothermic hypoxia at 37°C (Fig. 2A).
Preliminary data also showed that UW solution supplemented with mitochondria-targeted
H2S donor AP39 was more cytoprotective during 18h of hypoxia at 21°C than UW solution
supplemented with non-specific H2S donor GYY4137 (Fig. 2-2). Hence, AP39 was the
only donor used for both aims of this study.

Figure 2-2 Preliminary results. (A) Renal cell viability (%) following treatment with
UW solution during 12h of subnormothermic (21°C) or normothermic (37°C) hypoxia
and 24h of reoxygenation at 27°C in Media 199 (n=3). (B) Renal cell viability (%)
following treatment with UW, UW+GYY4137 or UW+AP39 during 18h of
subnormothermic hypoxia (21°C) and 24h of reoxygenation at 37°C in Media 199 (n=3).
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Ex vivo model of DCD porcine kidney preservation
Tissue necrosis was visualized to evaluate the impact of prolonged ex vivo porcine
kidney storage in AP39-supplemented UW solution at 21°C after causing warm ischemic
injury that mimics DCD injury (Fig. 2-3).

Figure 2-3 Ex vivo model of DCD porcine kidney preservation. A summary of the
experimental procedure used to visualize the level of tissue necrosis of DCD porcine
kidneys following prolonged ex vivo static storage for 24h in UW+200nM AP39 21°C vs.
UW solution at 4°C or at 21°C.
Surgery & induction of warm ischemia to mimic DCD
Kidneys were obtained from pigs weighing 30-65 kg that were being euthanized as
a part of other studies at Western University. The pigs were tranquilized and prepared for
surgery according to standard operating procedure. A midline incision was used to expose
the kidneys. The right and left kidneys with their ureters were dissected free from the retro
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peritoneum while leaving the blood supply to the ureter intact and then the ureter was
divided. The renal vascular pedicles were left as long as possible by freeing the renal artery
and vein up to the aorta and vena cava. The pedicles were clamped for 60 minutes to induce
warm ischemia in the donor organs following intravenous infusion of 3000 units of heparin.
This was done to mimic kidney injury that occurs during clinical DCD organ procurement.
Subsequently, nephrectomies of the left and right kidneys were performed. All the
surgeries were performed by transplant fellows at University Hospital, London, Ontario,
Canada. Other research groups harvested other organs of the donor animal and the donor
animal was euthanized. The surgical procedures received ethics approval from the Western
University Council for Animal Care.
Ex vivo organ preservation treatments
The kidneys were randomly assigned to one of three preservation treatment groups
for the prolonged organ storage period of 24h (Fig. 2-3). The first group of kidneys were
flushed with and stored in UW solution on ice (4°C), which reflects SCS, the current
clinical standard of care for organ preservation. The second group of kidneys were flushed
with and stored in UW solution at 21°C. The third groups of kidneys were flushed with
UW solution supplemented with 200nM AP39 and stored in the same solution at 21°C.
The groups labels are UW-4°C, UW-21°C and UW+AP39-21°C respectively. The dose of
AP39 added to UW solution was determined based on previous prolonged cold storage
experiments with rat kidneys where adding 200nM AP39 to UW solution during cold
storage resulted in lesser tissue injury and improved post-transplant graft outcome [27].
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Fluorescence staining to evaluate cellular necrosis
Following the 24h storage period, the kidneys were perfused with 50mL of 5µM
ethidium homodimer-1 (EthD-1) (InvitrogenTM, USA) diluted in 1X PBS at a rate of
5mL/min. EthD-1 is a fluorescent marker that binds to double-stranded DNA when the
plasma membrane of cells is compromised, which indicates necrosis. Subsequently, the
kidneys were washed by perfusion with 25mL of PBS at a rate of 1mL/min to flush out the
excess EthD-1 stain.
Imaging and data analysis
Following EthD-1 staining, kidney sections were stored in formalin for a minimum
of 72 hours, stained with the nuclear marker 4,6-diamidino-2-phenylindole (DAPI) and
analyzed via fluorescent microscopy. An Olympus (Toronto, Canada) IX83 Inverted
Microscope was used to capture five images per section for EthD-1 analysis and to capture
the equivalent DAPI images. All images were captured at 20X magnification. The total
proportion (%) of EthD-1+ area was quantified using ImageJ software v 1.50 (National
Institutes of Health, USA). Background fluorescence was subtracted and the RGB color
threshold was adjusted uniformly for all images to accurately quantify the level of EthD1+ staining. GraphPad Prism 7 was used to present the EthD-1+ % area values and oneway ANOVA and Tukey’s post-hoc test were performed to determine statistically
significant differences between treatment groups. Statistical significance was accepted at
p<0.05.
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2.4 Results
Supplementation of UW solution with mitochondria-targeted H2S donor AP39
increases renal tubular epithelial cell viability and decreases apoptosis during in vitro
subnormothermic renal IRI
To investigate the effect of supplementing UW solution with AP39 on renal tubular
epithelial cell viability during subnormothermic IRI, LLC-PK1 cells were treated with UW
solution supplemented with various concentrations of AP39 and subjected to 18h of
hypoxia at 21°C to mimic subnormothermic ischemia during organ storage. This was
followed by 24h of reoxygenation in media at 37°C to mimic reperfusion. Flow cytometry
analysis after staining for necrosis and apoptosis revealed a dose-dependent increase in the
percentage of unstained viable cells as the concentration of AP39 added to UW solution
was increased (Fig. 2-4A, 2-4B). While all the experimental samples exhibited
significantly lower renal tubular epithelial cell viability (p<0.05) than control cells grown
in normoxic conditions, cells treated with UW solution supplemented with 5µM and 10µM
AP39 exhibited significantly higher viability (p<0.05) than cells treated with only UW
solution (Fig. 2-4B). The reverse trend was observed with apoptosis, where cells treated
with UW solution supplemented with 5µM and 10µM AP39 exhibited significantly lower
apoptosis (p<0.05) than cells treated with UW solution alone. Interestingly, the level of
apoptosis exhibited by cells treated with UW solution supplemented with 5µM AP39 was
comparable to that of control cells grown in normoxic conditions (Fig. 2-4C). Additionally,
the dose-dependent increase in viability and decrease in apoptosis appears to reach
optimum levels when UW solution is supplemented 5µM AP39 and the addition of a higher
dose, 10µM AP39, begins to reverse these trends (Fig. 2-4B, 2-4C).
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Figure 2-4 AP39-supplemented UW solution improves renal tubular epithelial cell
survival in a dose-dependent manner during subnormothermic IRI. LLC-PK1 cells
were treated with UW solution supplemented with different concentrations of H2S donor
AP39. The treated cells were placed in hypoxia for 18h at 21°C and later reoxygenated in
Media 199 for 24h at 37°C. Following reoxygenation, cells were stained with FITCAnnexin-V and 7-AAD for flow cytometry analysis to quantify apoptosis and necrosis.
Control cells were grown in normoxic growth conditions in Media 199. All data were
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analyzed using FlowJo V10. (A) Representative images of flow cytometry results for all
treatment groups. (B) Mean cell viability (%) (n=5) as determined by the ratio of cells
negative for FITC-Annexin-V and 7-AAD staining. (C) Mean apoptosis (%) (n=5) as
determined by the ratio of cells positively stained for FITC-Annexin-V, but not 7-AAD.
Data represent mean ± SEM. Means were analyzed using one-way ANOVA and Tukey’s
post-hoc test. *, p<0.05 vs. control. , p<0.05 vs. UW Solution. ns, not significant
(p>0.05).
AP39-supplemented UW solution is more cytoprotective during subnormothermic
IRI than during warm IRI
LLC-PK1 cells were treated with UW solution supplemented with various
concentrations of AP39 and subjected to 18h of hypoxia at 21°C or 37°C to mimic ischemic
injury during subnormothermic or normothermic organ preservation. This was followed by
24h of reoxygenation in media at 37°C to mimic reperfusion injury. Flow cytometry
analysis revealed a dose-dependent increase in renal tubular epithelial cell viability
following warm IRI. While all the experimental samples exhibited significantly lower
viability (p<0.05) compared to control cells grown in normoxic conditions, cells treated
with UW solution supplemented with 10µM AP39 exhibited significantly higher viability
(p<0.05) than cells treated with UW solution alone (Fig. 2-5A). Additionally, all the
experimental

samples

displayed

significantly

higher

subnormothermic IRI than after warm IRI (Fig. 2-5B).

viability

(p<0.05)

after
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Figure 2-5 AP39-supplemented UW solution is more cytoprotective during
subnormothermic IRI than warm IRI. (A) Mean cell viability (%) after 18h of hypoxia
at 37°C (n=5) and 24h of reoxygenation at 37°C as determined by the ratio of cells negative
for FITC-Annexin-V and 7-AAD staining. (B) Mean cell viability (%) after 18h of hypoxia
at 21°C (n=5) or 37°C (n=5) and 24h of reoxygenation at 37°C. Data represent mean ±
SEM. Means in (A) were analyzed using one-way ANOVA and Tukey’s post-hoc test. *,
p<0.05 vs. control. , p<0.05 vs. UW Solution. Means in (B) were analyzed using multiple
t-tests and the Holm-Sidak method for multiple comparisons.

*, p<0.05.
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AP39-supplemented UW solution is more cytoprotective during cold IRI than during
subnormothermic IRI
LLC-PK1 cells were treated with UW solution supplemented with various
concentrations of AP39 and subjected to 18h of hypoxia at 10°C or 21°C to mimic ischemia
during cold or subnormothermic organ preservation. This was followed by 24h of
reoxygenation in media at 37°C to mimic reperfusion. Flow cytometry analysis revealed a
dose-dependent increase in renal tubular epithelial cell viability following 18h of hypoxia
at 10°C followed by 24h of reoxygenation at 37°C. While all the experimental samples
exhibited significantly lower viability (p<0.05) compared to control cells grown in
normoxic conditions, cells treated with UW solution supplemented with 5µM AP39
exhibited significantly higher viability (p<0.05) than cells treated with UW solution alone
(Fig. 2-6A). Additionally, cells treated with UW solution alone or UW solution
supplemented with 5nM, 50nM, 500nM and 5µM AP39 displayed significantly higher
viability (p<0.05) after cold IRI than after subnormothermic IRI. However, the difference
in viability exhibited by both groups decreases as the dose of AP39 increases (Fig. 2-6B).
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Figure 2-6 AP39-supplemented UW solution is more cytoprotective during cold IRI
than subnormothermic IRI. (A) Mean cell viability (%) after 18h of hypoxia at 10°C
(n=5) and 24h of reoxygenation at 37°C as determined by the ratio of cells negative for
FITC-Annexin-V and 7-AAD staining. (B) Mean cell viability (%) after 18h of hypoxia at
10°C (n=5) or 21°C (n=5) and 24h of reoxygenation at 37°C. Data represent mean ± SEM.
Means in (A) were analyzed using one-way ANOVA and Tukey’s post-hoc test. *, p<0.05
vs. control. , p<0.05 vs. UW Solution. Means in (B) were analyzed using multiple t-tests
and the Holm-Sidak method for multiple comparisons. *, p<0.05.
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Prolonged static subnormothermic storage of DCD kidneys in AP39supplemented UW solution at 21°C reduces tissue necrosis compared to static
cold storage in UW solution at 4°C
Porcine kidneys were nephrectomized after 1hr of renal pedicle clamping to mimic
clinical DCD organ donation. The kidneys were then flushed with and stored in either UW
solution at 4°C, UW solution at 21°C or UW solution supplemented with 200nM AP39 at
21°C for 24h. Following storage, the kidneys were flushed with 5µM EthD-1 stain to
visualize tissue necrosis. Formalin-fixed sections were stained with DAPI and analyzed for
EthD-1 and DAPI fluorescence using a confocal microscope (Fig. 2-7A). Fluorescence in
5 random fields of view per kidney was quantified using ImageJ to determine the mean
EthD-1+ area and DCD porcine kidneys stored in AP39-supplemented UW solution at
21°C exhibited the lowest mean EthD-1+ area. The mean EthD-1+ area of DCD kidneys
preserved in UW solution at 21°C was significantly higher than that of DCD kidneys stored
in AP39-supplemented UW solution at 21°C (p<0.001) and DCD kidneys stored in UW
solution at 4°C (p<0.05). Importantly, DCD kidneys stored in AP39-supplemented UW
solution at 21°C exhibited significantly lower (p<0.05) mean EthD-1+ area than DCD
kidneys preserved using SCS in UW solution at 4°C, which reflects the standard of care
(Fig. 2-7B).
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Figure 2-7 Prolonged static subnormothermic storage of DCD kidneys in AP39supplemented UW solution at 21°C reduces tissue necrosis compared to prolonged
static cold storage in UW solution at 4°C. Porcine kidneys were nephrectomized after
1hr of renal pedicle clamping to mimic DCD organ donation. The kidneys were flushed
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with and stored in either UW at 4°C (n=3), UW at 21°C (n=3) or UW+200nM AP39 at
21°C (n=6) for 24h. The kidneys were then flushed with 5µM EthD-1, stored in formalin,
sectioned and stained with DAPI. (A) Representative DAPI, EthD-1 (20X magnification)
and ImageJ quantification images for each treatment group. (B) Mean EthD-1+ area (%)
determined by analyzing five random fields of view for each kidney sample. Dots represent
mean EthD-1+ area (%) for individual kidneys and lines represent the mean EthD-1+ area
(%) ± SEM for each treatment group. Means were compared using one-way ANOVA and
Tukey’s post-hoc test. *, p<0.05. **, p<0.01.
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2.5 Discussion
IRI is an inevitable consequence of the transplantation process and it is a major
concern because renal IRI has been associated with DGF, acute graft rejection and early
graft loss following renal transplantation [6]. Organ preservation prior to transplantation
is one of the key steps of interest in terms of mitigating renal IRI. Currently, the clinical
standard of care for renal graft preservation is SCS at 4°C in a preservation solution such
as UW solution [16]. The hypothermic conditions reduce cellular metabolism to promote
survival until transplantation. However, the resulting cold IRI has been linked to increased
DGF, increased risk of graft failure and decreased long-term graft survival [16–18]. While
exogenous H2S therapy has been shown to mitigate the effects of cold IRI, normothermic
and subnormothermic preservation have become an important avenue of interest to prevent
cold IRI. While NMP and SMP have been shown to improve renal graft outcomes
compared to SCS, the cost and complexity of these techniques along with the lack of an
optimized standard protocol are challenges that need to be overcome [23, 32–37]. As a
result, a normothermic or subnormothermic equivalent of SCS, where the organ is kept at
37°C or at room temperature in a preservation solution along with other therapeutic
compounds, is of interest. In this study, we demonstrate, for the first time, that
mitochondria-targeted H2S donor AP39 makes the gold standard preservation solution,
UW solution, viable for subnormothermic organ preservation at 21°C.
Firstly, the effectiveness of UW solution, with and without AP39, at various
organ preservation temperatures was investigated using an in vitro model of renal IRI. Our
preliminary results showed that UW solution is more cytoprotective during
subnormothermic IRI than normothermic IRI. Consistent with the preliminary results, the
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cytoprotective effects of AP39-supplemented UW solution were also temperaturedependent as it was the most cytoprotective during cold IRI and the least cytoprotective
following normothermic IRI. These results were expected because UW solution was
designed for cold storage and they are consistent with our previous findings about the
effects of AP39 in cold IRI [27]. However, as the dose of AP39 added to UW solution
increased, the gap between the renal tubular epithelial cell viability levels following cold
IRI and subnormothermic IRI decreased. Therefore, we postulated that preservation at
21°C with AP39-supplemented UW solution has the potential to match cold storage in UW
solution alone, depending on the concentration of AP39 used. Overall, our in vitro results
show that mitochondria-targeted H2S therapy makes the existing gold standard
preservation solution, UW solution, viable for subnormothermic organ preservation of
renal grafts at 21°C.
Our findings of the temperature-dependent protective effects of UW solution are
also consistent with a study by Iwai et al., however, an important factor to consider is the
type of preservation solution being used [38]. UW solution is an intracellular-type
preservation solution, which means that it has a low-sodium/high-potassium composition
that mimics intracellular fluid [38]. In this study, we chose to evaluate H2S-supplemented
UW solution for subnormothermic and normothermic preservation due to our previous
work, which shows that cold storage with H2S-supplemented UW solution improved renal
graft outcomes [25–27]. However, in addition to comparing the outcomes of renal grafts
preserved in UW solution at 4°C, 23°C and 37°C, Iwai et al. also compared UW solution
to an extracellular-type solution, which has a high-sodium/low-potassium composition that
mimics extracellular fluid, called ET-Kyoto (ETK) solution [38]. They found that ETK
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solution was more suitable for normothermic preservation than UW solution, however,
both solutions were comparable for subnormothermic preservation [38]. They suggested
that the difference in the performance of ETK and UW solution during normothermic
preservation is due to the difference in the phase temperature of the main carbohydrates,
which are added to prevent cellular edema [38]. ETK solution contains trehalose, which
has a phase transition temperature of 24°C, while UW solution contains raffinose, which
has a phase transition temperature of 17°C [38–40]. This may explain why UW solution is
unsuitable for normothermic preservation and somewhat suitable for subnormothermic
preservation. The addition of AP39 to UW solution in this study likely improves its
viability for subnormothermic preservation due to the diverse cytoprotective effects of H2S.
Further research that compares intracellular-type solutions to extracellular-type solutions
is needed to establish the ideal static subnormothermic preservation protocol and the
optimal exogenous H2S therapy. However, we chose to use UW solution in this study
because it is the most mainstream preservation solution used worldwide and any findings
using UW solution would be widely applicable to clinical practice. In addition to low
sodium, high potassium and raffinose, UW solution also contains antioxidant components,
such as allopurinol and glutathione, along with lactobionate and hydroxyethyl starch to
prevent cellular edema [41]. There is no existing evidence to suggest that AP39 chemically
interacts with any of the components of UW solution, however, further research is needed
to confirm this.
With both the cold IRI and subnormothermic IRI models in the in vitro arm of
this study, 5 µM AP39 was the most effective concentration that led to the highest renal
tubular epithelial cell viability. Cells treated with UW+ 5 µM AP39 during
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subnormothermic IRI not only exhibited significantly higher viability than cells treated
with UW solution alone, but they also exhibited significantly lower apoptosis. This
suggests that the anti-apoptotic effects of H2S play an important role in making UW
solution viable for subnormothermic preservation. Apoptosis has been established as a
major mechanism underlying renal IRI-induced tissue damage and both the intrinsic and
extrinsic apoptotic pathways play a role [42]. Renal IRI has been shown to upregulate the
expression of pro-apoptotic genes such as FADD, Bad, Bak and p53 [43]. Bax and Bak
oligomers serve as the outer mitochondrial membrane component of the MPTP. The
opening of MPTPs is a key step in the intrinsic apoptotic pathway that allows pro-apoptotic
factors, such as cytochrome c, to be released into the cytoplasm. Cytochrome c facilitates
the oligomerization of caspase-9 and Apaf-1, which activates caspase-9 and allows it to
cleave other caspases to carry out widespread apoptotic events [42]. H2S has been shown
to counteract multiple pro-apoptotic mechanisms. Via persulfidation, AP39 can induce
cytochrome c-dependent protein sulfide signaling, which leads to inactivation of caspase 9
via persulfidation [44]. H2S also decreases the expression of pro-apoptotic genes, such as
Bid, which can facilitate crosstalk between the intrinsic and extrinsic apoptotic pathways
[26,42]. Additionally, H2S can decrease ROS production by scavenging ROS directly or
by upregulating cellular antioxidant defenses [45]. Using in vitro and in vivo models of
renal IRI and transplantation, we have previously shown that treatment with AP39
mitigates tissue apoptosis, reduces ROS production and prevents mitochondrial
depolarization during cold IRI [27]. Thus, H2S facilitates a variety of direct and indirect
anti-apoptotic mechanisms, especially in the mitochondria, which may be contributing to
the superior effects of mitochondria-targeted H2S donors, such as AP39, compared to non-
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targeted donors [27]. Future studies are warranted to elucidate the mechanisms underlying
the cytoprotective effects of AP39-supplemented UW solution during subnormothermic
preservation that were observed in this study.
Based on the in vitro results, we decided to investigate the effects of storing renal
grafts in AP39-supplemented UW solution at 21°C. Tissue necrosis was visualized after
DCD porcine kidneys were preserved for 24h using SCS at 4°C in UW solution, which
reflects the clinical standard of care, or subnormothermic storage at 21°C in UW solution
with or without 200nM AP39. The dose of AP39 added to the UW solution was determined
based on the in vivo results of our previous study [27]. Prolonged subnormothermic storage
at 21°C in AP39-supplemented UW solution led to significantly lower tissue necrosis than
subnormothermic storage in UW solution and SCS in UW solution alone at 4°C, which is
the clinical standard of care. These results are consistent with our in vitro results, which
showed that the addition of AP39 makes UW solution more viable for subnormothermic
organ preservation at 21°C. These results also suggest that this approach has the potential
to match or surpass SCS in UW solution alone, depending on the concentration of AP39
used. The effectiveness of 200nM AP39 in this model is consistent with our previous
findings [27].
As discussed earlier, a large body of evidence shows the role of apoptosis in
tubular cell death caused by renal IRI and several studies have shown the anti-apoptotic
effects of H2S in renal IRI [26,27,42,43]. However, emerging evidence suggests that
RIPK3/RIP3-induced necroptosis is also involved in IRI-induced tubular cell death
[46,47]. Using a mouse model of allotransplantation, Lau et al. showed that RIPK3-/- donor
kidneys exhibit tissue necrosis, which was determined via EthD-1 fluorescence, along with
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improved post-transplant outcomes [46]. Interestingly, a recent study by Lin et al. shows
that exogenous H2S can reduce the expression of RIP3 and reduce necroptotic injury of
hyperglycemic human umbilical vein endothelial cells [48]. While the effect of exogenous
H2S on RIP3-induced necroptosis has not be studied in the context of renal IRI, it is
possible that such an effect is contributing to the decreased level of tissue necrosis observed
after prolonged DCD kidney preservation in AP39-supplemented UW solution at 21°C.
Future studies evaluating RIP3 expression after preservation of renal grafts with and
without H2S are needed to confirm this effect.
While our prolonged ex vivo DCD kidney storage model allows visualization of
tissue injury, the lack of post-transplant graft function analysis and small sample sizes are
limitations. However, there are several key advantages of using this model. Firstly, the
warm ischemic injury inflicted in this model not only mimics clinical DCD organ donation
but is likely more severe due to the complete cessation of blood flow via clamping rather
than the gradual ischemic injury that occurs during cardiac death. Thus, seeing as DCD
kidneys stored in AP39-supplemented UW solution at 21°C show low tissue necrosis in
this model, this storage treatment would likely be as or more effective in reducing the tissue
necrosis of discarded human DCD kidneys in future studies. Secondly, the prolonged 24h
storage time is at the higher end of conventional organ preservation times in clinical renal
transplantation, which range from 6-36h [49,50]. Both of these aspects reflect clinically
relevant conditions and the use of porcine kidneys is a third advantage, due to their
similarity to human kidneys in terms of size and structure [51,52]. Overall, our results show
that static storage of DCD kidneys in AP39-suppelemented UW solution at 21°C is better
than the clinical standard of care in terms of reducing renal tissue injury. However, further
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research is needed to evaluate the function of DCD kidneys preserved in AP39suppelemented UW solution at 21°C.
In conclusion, we demonstrate, for the first time, that exogenous H2S therapy
with mitochondria-targeted H2S donor AP39 improves the viability of the gold standard
kidney preservation solution, UW solution, for subnormothermic preservation at 21°C.
Subnormothermic preservation at 21°C is likely effective because it prevents the damage
caused by cold storage while allowing the use of conventional preservation solutions that
were designed for cold storage, such as UW solution. Additionally, supplementing UW
solution with H2S likely mitigates the negative effects of the higher metabolic demand at
21°C compared to 4°C with cold storage. Thus, subnormothermic preservation at 21°C
with exogenous H2S therapy represents a novel avenue in organ preservation. However,
further research, using ex vivo reperfusion and in vivo transplantation models, is needed to
evaluate the function of renal grafts preserved using static subnormothermic storage at
21°C in H2S-supplemented UW solution and this study will provide the foundation for that
work. In terms of post-transplant function, this approach also needs to be compared to the
clinical standard of care, SCS in UW solution, along with SMP at 21°C and NMP with
H2S-supplemented blood or other solutions. It is possible that subnormothermic
preservation at 21°C using H2S, including static storage and machine perfusion, may match
or surpass SCS, because it prevents cold IRI-induced damage, and NMP, because it
promotes recovery in a phase of lower metabolic demand at 21°C rather than at 37°C.
Ultimately, if successful, these studies could substantiate the translation of static
subnormothermic preservation at 21°C with H2S into clinical practice. The clinical
implementation of this approach would eliminate the negative consequences of cold
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storage and it could expand the pool of acceptable donor organs by promoting the recovery
of sub-optimal donor organs.

2.6 References
[1]

Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, et al.
Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting
Transplantation, and Recipients of a First Cadaveric Transplant. N Engl J Med
[Internet]. 1999 Dec 2 [cited 2018 Apr 8];341(23):1725–30. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/10580071

[2]

Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic
Review: Kidney Transplantation Compared With Dialysis in Clinically Relevant
Outcomes. Am J Transplant [Internet]. 2011 Oct [cited 2018 Apr 8];11(10):2093–
109. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21883901

[3]

Cavallo MC, Sepe V, Conte F, Abelli M, Ticozzelli E, Bottazzi A, et al. CostEffectiveness of Kidney Transplantation From DCD in Italy. Transplant Proc
[Internet]. 2014 Dec [cited 2018 Apr 8];46(10):3289–96. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25498039

[4]

Saat TC, van den Akker EK, IJzermans JNM, Dor FJMF, de Bruin RWF.
Improving the outcome of kidney transplantation by ameliorating renal ischemia
reperfusion injury: lost in translation? J Transl Med [Internet]. 2016 Jan 20 [cited
2018 Apr 8];14:20. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26791565

[5]

Annual Statistics on Organ Replacement in Canada. Can Inst Heal Inf [Internet].

83

2017 [cited 2018 Apr 8]; Available from:
https://www.cihi.ca/sites/default/files/document/corr_ar-snapshot-en.pdf
[6]

Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk
factors and implications for renal allograft survival. Transplantation [Internet].
1997 Apr 15 [cited 2018 Apr 8];63(7):968–74. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/9112349

[7]

Kako K, Kato M, Matsuoka T, Mustapha A. Depression of membrane-bound Na+K+-ATPase activity induced by free radicals and by ischemia of kidney. Am J
Physiol Physiol [Internet]. 1988 Feb [cited 2018 Apr 8];254(2):C330–7. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/2831728

[8]

Kato M, Kako KJ. Effects of N-(2-mercaptopropionyl)glycine on ischemicreperfused dog kidney in vivo and membrane preparation in vitro. Mol Cell
Biochem [Internet]. 1987 Dec [cited 2018 Apr 8];78(2):151–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/2831450

[9]

Salvadori M, Rosso G, Bertoni E. Update on ischemia-reperfusion injury in kidney
transplantation: Pathogenesis and treatment. World J Transplant [Internet]. 2015
Jun 24 [cited 2018 Apr 8];5(2):52–67. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26131407

[10]

Kezic A, Spasojevic I, Lezaic V, Bajcetic M. Mitochondria-Targeted Antioxidants:
Future Perspectives in Kidney Ischemia Reperfusion Injury. Oxid Med Cell
Longev [Internet]. 2016 May 24 [cited 2018 Apr 8];2016:1–12. Available from:
http://www.hindawi.com/journals/omcl/2016/2950503/

[11]

Peng T-I, Jou M-J. Oxidative stress caused by mitochondrial calcium overload.

84

Ann N Y Acad Sci [Internet]. 2010 Jul [cited 2018 Apr 8];1201(1):183–8.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20649555
[12]

Jassem W, Fuggle S V, Rela M, Koo DDH, Heaton ND. The role of mitochondria
in ischemia/reperfusion injury. Transplantation [Internet]. 2002 Feb 27 [cited 2018
Apr 8];73(4):493–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/11889418

[13]

Arduini A, Mezzetti A, Porreca E, Lapenna D, DeJulia J, Marzio L, et al. Effect of
ischemia and reperfusion on antioxidant enzymes and mitochondrial inner
membrane proteins in perfused rat heart. Biochim Biophys Acta [Internet]. 1988
Jun 30 [cited 2018 Apr 8];970(2):113–21. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/3382695

[14]

Jassem W, Ciarimboli C, Cerioni PN, Saba V, Norton SJ, Principato G. Glyoxalase
II and glutathione levels in rat liver mitochondria during cold storage in EuroCollins and University of Wisconsin solutions. Transplantation [Internet]. 1996
May 15 [cited 2018 Apr 8];61(9):1416–20. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/8629310

[15]

Rouslin W. Mitochondrial complexes I, II, III, IV, and V in myocardial ischemia
and autolysis. Am J Physiol Circ Physiol [Internet]. 1983 Jun [cited 2018 Apr
8];244(6):H743–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6305212

[16]

Guibert EE, Petrenko AY, Balaban CL, Somov AY, Rodriguez J V, Fuller BJ.
Organ Preservation: Current Concepts and New Strategies for the Next Decade.
Transfus Med Hemother [Internet]. 2011 [cited 2018 Apr 8];38(2):125–42.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21566713

85

[17]

Debout A, Foucher Y, Trébern-Launay K, Legendre C, Kreis H, Mourad G, et al.
Each additional hour of cold ischemia time significantly increases the risk of graft
failure and mortality following renal transplantation. Kidney Int [Internet]. 2015
Feb [cited 2018 Apr 8];87(2):343–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25229341

[18]

Salahudeen AK, Haider N, May W. Cold ischemia and the reduced long-term
survival of cadaveric renal allografts. Kidney Int [Internet]. 2004 Feb [cited 2018
Apr 8];65(2):713–8. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/14717946

[19]

Bon D, Chatauret N, Giraud S, Thuillier R, Favreau F, Hauet T. New strategies to
optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol
[Internet]. 2012 Jun 1 [cited 2018 Apr 8];8(6):339–47. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/22549229

[20]

Moers C, Smits JM, Maathuis M-HJ, Treckmann J, van Gelder F, Napieralski BP,
et al. Machine Perfusion or Cold Storage in Deceased-Donor Kidney
Transplantation. N Engl J Med [Internet]. 2009 Jan 1 [cited 2018 Apr 8];360(1):7–
19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19118301

[21]

Merion RM, Oh HK, Port FK, Toledo-Pereyra LH, Turcotte JG. A prospective
controlled trial of cold-storage versus machine-perfusion preservation in cadaveric
renal transplantation. Transplantation [Internet]. 1990 Aug [cited 2018 Apr
9];50(2):230–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2382290

[22]

Monbaliu D, Heedfeld V, Liu Q, Wylin T, van Pelt J, Vekemans K, et al.
Hypothermic Machine Perfusion of the Liver: Is It More Complex than for the

86

Kidney? Transplant Proc [Internet]. 2011 Nov [cited 2018 Apr 9];43(9):3445–50.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22099817
[23]

Catena F, Coccolini F, Montori G, Vallicelli C, Amaduzzi A, Ercolani G, et al.
Kidney Preservation: Review of Present and Future Perspective. Transplant Proc
[Internet]. 2013 Nov [cited 2018 Apr 8];45(9):3170–7. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24182779

[24]

Meng G, Wang J, Xiao Y, Bai W, Xie L, Shan L, et al. GYY4137 protects against
myocardial ischemia and reperfusion injury by attenuating oxidative stress and
apoptosis in rats. J Biomed Res [Internet]. 2015 May 30 [cited 2018 Apr
11];29(3):203–13. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26060444

[25]

Lobb I, Davison M, Carter D, Liu W, Haig A, Gunaratnam L, et al. Hydrogen
Sulfide Treatment Mitigates Renal Allograft Ischemia-Reperfusion Injury during
Cold Storage and Improves Early Transplant Kidney Function and Survival
Following Allogeneic Renal Transplantation. J Urol [Internet]. 2015 Dec [cited
2018 Apr 11];194(6):1806–15. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26239336

[26]

Lobb I, Mok A, Lan Z, Liu W, Garcia B, Sener A. Supplemental hydrogen
sulphide protects transplant kidney function and prolongs recipient survival after
prolonged cold ischaemia-reperfusion injury by mitigating renal graft apoptosis
and inflammation. BJU Int [Internet]. 2012 Dec [cited 2018 Apr
11];110(11c):E1187–95. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23157304

87

[27]

Lobb I, Jiang J, Lian D, Liu W, Haig A, Saha MN, et al. Hydrogen Sulfide
Protects Renal Grafts Against Prolonged Cold Ischemia-Reperfusion Injury via
Specific Mitochondrial Actions. Am J Transplant [Internet]. 2017 Feb [cited 2018
Apr 11];17(2):341–52. Available from: http://doi.wiley.com/10.1111/ajt.14080

[28]

Zhao Y, Biggs TD, Xian M. Hydrogen sulfide (H2S) releasing agents: chemistry
and biological applications. Chem Commun (Camb) [Internet]. 2014 Oct 14 [cited
2018 Apr 12];50(80):11788–805. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25019301

[29]

Szczesny B, Módis K, Yanagi K, Coletta C, Le Trionnaire S, Perry A, et al. AP39,
a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular
bioenergetics, exerts cytoprotective effects and protects against the loss of
mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro.
Nitric oxide Biol Chem [Internet]. 2014 Sep 15 [cited 2018 Apr 11];41:120–30.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24755204

[30]

Hosgood SA, van Heurn E, Nicholson ML. Normothermic machine perfusion of
the kidney: better conditioning and repair? Transpl Int [Internet]. 2015 Jun [cited
2018 Apr 12];28(6):657–64. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24629095

[31]

Imber CJ, St Peter SD, Lopez de Cenarruzabeitia I, Pigott D, James T, Taylor R,
et al. Advantages of normothermic perfusion over cold storage in liver
preservation. Transplantation [Internet]. 2002 Mar 15 [cited 2018 Apr
12];73(5):701–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11907414

[32]

Kaths JM, Echeverri J, Chun YM, Cen JY, Goldaracena N, Linares I, et al.

88

Continuous Normothermic Ex Vivo Kidney Perfusion Improves Graft Function in
Donation After Circulatory Death Pig Kidney Transplantation. Transplantation
[Internet]. 2017 Apr [cited 2018 Apr 12];101(4):754–63. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27467537
[33]

Bagul A, Hosgood SA, Kaushik M, Kay MD, Waller HL, Nicholson ML.
Experimental renal preservation by normothermic resuscitation perfusion with
autologous blood. Br J Surg [Internet]. 2007 Aug 15 [cited 2018 Apr
12];95(1):111–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17696214

[34]

Hosgood SA, Nicholson ML. First in Man Renal Transplantation After Ex Vivo
Normothermic Perfusion. Transplantation [Internet]. 2011 Oct 15 [cited 2018 Apr
12];92(7):735–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21841540

[35]

Nicholson ML, Hosgood SA. Renal transplantation after ex vivo normothermic
perfusion: the first clinical study. Am J Transplant [Internet]. 2013 May [cited
2018 Apr 12];13(5):1246–52. Available from:
http://doi.wiley.com/10.1111/ajt.12179

[36]

Hoyer DP, Gallinat A, Swoboda S, Wohlschläger J, Rauen U, Paul A, et al.
Subnormothermic machine perfusion for preservation of porcine kidneys in a
donation after circulatory death model. Transpl Int [Internet]. 2014 Oct [cited 2018
Apr 12];27(10):1097–106. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24963744

[37]

El Sabbahy M, Vaidya VS. Ischemic kidney injury and mechanisms of tissue
repair. Wiley Interdiscip Rev Syst Biol Med [Internet]. 2011 [cited 2018 Apr
12];3(5):606–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21197658

89

[38]

Iwai S, Kikuchi T, Kasahara N, Teratani T, Yokoo T, Sakonju I, et al. Impact of
Normothermic Preservation with Extracellular Type Solution Containing
Trehalose on Rat Kidney Grafting from a Cardiac Death Donor. Mandell MS,
editor. PLoS One [Internet]. 2012 Mar 21 [cited 2018 Apr 12];7(3):e33157.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22457739

[39]

Chen T, Fowler A, Toner M. Literature Review: Supplemented Phase Diagram of
the Trehalose–Water Binary Mixture. Cryobiology [Internet]. 2000 May [cited
2018 Aug 15];40(3):277–82. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/10860627

[40]

Crowe JH, Carpenter JF, Crowe LM. THE ROLE OF VITRIFICATION IN
ANHYDROBIOSIS. Annu Rev Physiol [Internet]. 1998 Oct [cited 2018 Aug
15];60(1):73–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9558455

[41]

Southard JH, Belzer FO. The University of Wisconsin organ preservation solution:
Components, comparisons, and modifications. Transplant Rev [Internet]. 1993 Oct
1 [cited 2018 Oct 11];7(4):176–90. Available from: https://www-sciencedirectcom.proxy1.lib.uwo.ca/science/article/pii/S0955470X05800254

[42]

Sanz AB, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A. Mechanisms of Renal
Apoptosis in Health and Disease. J Am Soc Nephrol [Internet]. 2008 Aug 6 [cited
2018 Apr 15];19(9):1634–42. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18632846

[43]

Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P.
Differential gene expression following early renal ischemia/reperfusion. Kidney
Int [Internet]. 2003 May [cited 2018 Apr 15];63(5):1714–24. Available from:

90

http://www.ncbi.nlm.nih.gov/pubmed/12675847
[44]

Vitvitsky V, Miljkovic JL, Bostelaar T, Adhikari B, Yadav PK, Steiger AK, et al.
Cytochrome c Reduction by H 2 S Potentiates Sulfide Signaling. ACS Chem Biol
[Internet]. 2018 Jul 18 [cited 2018 Jul 23];acschembio.8b00463. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/29966080

[45]

Lobb I, Sonke E, Aboalsamh G, Sener A. Hydrogen sulphide and the kidney:
Important roles in renal physiology and pathogenesis and treatment of kidney
injury and disease. Nitric Oxide - Biol Chem [Internet]. 2015;46:55–65. Available
from: http://dx.doi.org/10.1016/j.niox.2014.10.004

[46]

Lau A, Wang S, Jiang J, Haig A, Pavlosky A, Linkermann A, et al. RIPK3Mediated Necroptosis Promotes Donor Kidney Inflammatory Injury and Reduces
Allograft Survival. Am J Transplant [Internet]. 2013 Nov [cited 2018 Apr
14];13(11):2805–18. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24103001

[47]

Zhu Y, Cui H, Xia Y, Gan H. RIPK3-Mediated Necroptosis and Apoptosis
Contributes to Renal Tubular Cell Progressive Loss and Chronic Kidney Disease
Progression in Rats. PLoS One [Internet]. 2016 [cited 2018 Apr
14];11(6):e0156729. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27281190

[48]

Lin J, Chen M, Liu D, Guo R, Lin K, Deng H, et al. Exogenous hydrogen sulfide
protects human umbilical vein endothelial cells against high glucose‑induced
injury by inhibiting the necroptosis pathway. Int J Mol Med [Internet]. 2018 Mar
[cited 2018 Apr 14];41(3):1477–86. Available from:

91

http://www.ncbi.nlm.nih.gov/pubmed/29286079
[49]

Michel SG, LaMuraglia Ii GM, Madariaga MLL, Anderson LM. Innovative cold
storage of donor organs using the Paragonix Sherpa Pak TM devices. Hear lung
Vessel [Internet]. 2015 [cited 2018 Apr 14];7(3):246–55. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26495271

[50]

McLaren AJ, Friend PJ. Trends in organ preservation. Transpl Int [Internet]. 2003
Oct 1 [cited 2018 Apr 14];16(10):701–8. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/14530855

[51]

Giraud S, Favreau F, Chatauret N, Thuillier R, Maiga S, Hauet T. Contribution of
large pig for renal ischemia-reperfusion and transplantation studies: the preclinical
model. J Biomed Biotechnol [Internet]. 2011 [cited 2018 Apr 14];2011:532127.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21403881

[52]

Cowan PJ, Cooper DKC, d’Apice AJF. Kidney xenotransplantation. Kidney Int
[Internet]. 2014 Feb [cited 2018 Apr 14];85(2):265–75. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24088952

92

Chapter 3

3

Subnormothermic perfusion with H2S donor AP39
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3.1 Abstract
Cold preservation is the standard of care for renal grafts. However, research on
alternatives like perfusion at higher temperatures and supplementing preservation solutions
with hydrogen sulfide (H2S) has gained momentum. In this study, we investigate whether
adding H2S donor AP39 to porcine blood during subnormothermic perfusion at 21°C
improves renal graft outcomes. Porcine kidneys were nephrectomized after 30 minutes of
clamping the renal pedicles and treated to 4h of static cold storage on ice (SCS) or ex vivo
subnormothermic perfusion at 21°C with autologous blood alone (SNT) or with AP39
(SNTAP). All kidneys were reperfused ex vivo with autologous blood at 37°C for 4h. Urine
output, histopathology and RNAseq were used to evaluate renal graft function, injury and
gene expression profiles respectively. The SNTAP group exhibited significantly higher
urine output than other groups during preservation and reperfusion, along with significantly
lower apoptotic injury compared to the SCS group. The SNTAP group also exhibited
differential pro-survival gene expression patterns compared to the SCS (downregulation of
pro-apoptotic genes) and SNT (downregulation of hypoxia response genes) groups.
Subnormothermic perfusion at 21°C with H2S-supplemented blood improves renal graft
outcomes. Further research is needed to facilitate the clinical translation of this approach.
Gene Abbreviations: AJUBA – Lim-domain containing protein AJUBA, BAG3 – Bcl2-associated
anthanogene (BAG) family chaperone regulator 3, BCL10 – B-cell lymphoma/leukemia 10, DDIT3
– DNA damage -inducible transcript 3, EGR1 – Early growth response protein 1, HOXD8/10 –
Homeobox protein Hox-D8/10, HSPA1A – Heat shock 70kDa protein 1A, HSPD1- Heat shock
protein 60kDa, mitochondrial, IL6 – Interleukin 6, MAPK7 – Mitogen-activated protein kinase 7,
NRROS – Negative regulator of reactive oxygen species, PCK1 – Phosphoenolpyruvate
carboxykinase, cytosolic, PDK3 – Pyruvate dehydrogenase kinase, mitochondrial, RGCC –
Regulator of cell cycle, SMAD3 – Mothers against decapentaplegic homolog 3, TGF-β –
Transforming growth factor β
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3.2 Introduction
Over the past 25 years, hydrogen sulfide (H2S) has become known as the third
gasotransmitter, following nitric oxide and carbon monoxide, and the body of literature
about its roles in all cells and tissues continues to expand [1–3]. One interesting therapeutic
application of H2S is its use in kidney graft preservation to improve renal transplant
outcomes. Renal transplantation is the preferred treatment for end stage renal disease
because it enhances quality of life and survival compared to hemodialysis [4]. The demand
for transplantable kidneys, however, outweighs the supply. As a result, kidneys obtained
via donation after cardiac death (DCD) are being used more often in transplant centres
across the globe [5]. DCD kidneys typically exhibit higher rates of delayed graft function
(DGF) and poor long-term survival [6,7]. This is due to the greater ischemic injury
experienced by DCD grafts compared to living donor organs. Kidneys from living donors
experience some cold ischemic injury from the time of harvest to reimplantation. However,
DCD kidneys experience prolonged periods of warm ischemia, as cardiac death occurs,
and cold ischemia, during organ preservation. This leads to more severe ischemiareperfusion injury (IRI) upon reimplantation, which contributes to DGF and other poor
outcomes exhibited by DCD kidneys [8].
Organ preservation is a critical phase in terms of mitigating IRI. The clinical
standard of care for renal graft preservation is static cold storage (SCS), where the organ
is placed on ice (~4°C) in a bag with preservation solution. The alternative is hypothermic
machine perfusion (HMP), where the organ is perfused with cold preservation solution.
While this approach improves the distribution of nutrients and improves DCD graft
outcomes compared to SCS [9,10], it is used less frequently due to its higher cost and
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logistical challenges [11,12]. Importantly, both approaches are limited by the shutdown of
cellular metabolism inherent to cold preservation, which causes renal injury while
improving survival in cold conditions. Longer cold ischemia times are linked to poorer
DCD graft outcomes, including higher rates of DGF [13]. As a result, therapeutic strategies
that mitigate cold IRI of interest. One therapeutic approach is supplementing preservation
solutions with H2S due to its vasodilatory, anti-apoptotic and other cytoprotective effects
during IRI [14–16]. We have previously shown that supplementing preservation solutions
with H2S, especially mitochondria-targeted H2S donor AP39, during SCS improves murine
renal graft outcomes [15,16]. However, the context of cold preservation remains. Thus,
alternative approaches that facilitate kidney preservation at higher temperatures (20-37°C)
are also of interest [17].
Normothermic machine perfusion, which involves ex vivo perfusion of the
kidney at 37°C with a blood-based or acellular solutions, has been shown to improve renal
graft outcomes compared to SCS and HMP in several porcine DCD renal transplantation
studies [18,19]. In a 2011 pilot surgical case, it was reported that a short duration of this
approach after SCS improved clinical post-transplant outcomes compared to SCS alone
[20]. Additionally, several ongoing clinical trials are looking to validate and establish a
clinical protocol for normothermic preservation. However, in moving away from cold
preservation, research into subnormothermic preservation at temperatures (15-35°C) has
also gained momentum. In 2014, Hoyer et al. reported that, compared to SCS and HMP,
subnormothermic machine perfusion of DCD porcine kidneys at 20°C improved blood
flow, output and creatinine clearance during reperfusion with autologous blood [21]. Our
group has previously shown that adding AP39 to University of Wisconsin (UW) solution,
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a preservation solution that is routinely used for SCS, made it viable for subnormothermic
preservation at 21°C [22]. We have also shown that subnormothermic perfusion at 21°C
improved DCD porcine renal graft outcomes compared to SCS, subnormothermic
perfusion at 15°C, and normothermic perfusion at 37°C [23]. In this study, we investigate
whether subnormothermic perfusion at 21°C with H2S donor AP39 improves DCD porcine
renal graft outcomes compared to SCS and subnormothermic perfusion without AP39,
using ex vivo pulsatile perfusion for preservation and reperfusion.
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3.3 Materials and Methods
Animal care and surgery
Ten yorkshire pigs (60-70kg), purchased from a regional farm, were tranquilized
and routinely prepped for surgery. A midline incision was used to expose the kidneys
(n=20). The renal pedicles were clamped in situ for 30 minutes to induce warm ischemia,
to mimic DCD injury, following intravenous infusion of 10000 units of heparin. By
completely stopping renal blood flow, we replicate an extreme clinical DCD scenario
where there is no oxygen being supplied to the kidneys. This approach has been used in
many other studies within this field [18,21]. The ureters and arteries were cannulated to
facilitate ex vivo perfusion and urine collection. Subsequently, both kidneys were
nephrectomized and the donor animal was euthanized. Autologous blood used for
perfusion was collected via cannulation of the inferior vena cava before and after clamping
the renal pedicles.[23] Blood collected prior to clamping is referred to as non-stressed
blood because there is no interruption of blood flow. However, blood collected after
clamping is referred to as stressed blood due to the buildup of metabolites and signaling
molecules due resulting from the lack of blood flow through the kidneys. Surgeries were
performed by transplant fellows at University Hospital, London, Canada. All procedures
were approved by University of Western Ontario’s Animal Use Committee.
Treatments and ex vivo perfusion setup
The kidneys were assigned to one of three preservation treatments (Fig. 3-1A).
The first group of kidneys were flushed with and stored in UW solution on ice for 4h (SCS),
which reflects the clinical standard of care. The second group of kidneys were flushed with
UW solution and treated to 4h of subnormothermic perfusion at 21°C with non-stressed
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blood (SNT). The third group of kidneys were flushed with UW solution supplemented
with 200 nM AP39 and treated to 4h of subnormothermic perfusion at 21°C with nonstressed blood supplemented with 200 nM AP39 (SNTAP). After the 4h preservation
period, all kidneys were perfused with stressed autologous blood for 4h at 37°C to simulate
reperfusion after renal transplantation. A total of ten pig kidney perfusion experiments were
performed. In the first seven experiments, left and right kidneys were randomly assigned
to either the SCS group (n=7) or the SNTAP group (n=7), with both kidneys connected to
the same cassette during reperfusion with stressed blood. Pairs of kidneys sharing the blood
reservoir was unavoidable due to the limitation of having a single pulsatile pump. In the
following three experiments, both the left and right kidneys were assigned to the SNT
group (n=6) as this was an additional control group to represent the effects of
subnormothermic perfusion without AP39. The dose of AP39 was chosen based on a
previous in vivo murine transplantation study by our group [10]. The kidneys were perfused
using an ex vivo pulsatile perfusion apparatus (Fig. 3-1B), which was identical to the setup
used in a previous study by our centre [23]. Through adjusting the flow, the mean perfusion
pressure was maintained at 60 mmHg after an initial 5-minute period of gradual increase.
The blood used in the perfusion circuits was oxygenated using an external oxygen gas
supply and no supplemental nutrients, vasodilators or diuretics were added at any point.
This was done to evaluate the effect of subnormothermic perfusion with and without AP39
compared to SCS in a simplistic manner without any confounding variables. Urine output
was recorded hourly and PlasmaLyte solution (Baxter, IL) was used to compensate for
fluid volume loss. Kidney samples were collected after reperfusion with stressed blood,

99

kidneys were bivalved sagittally. One half was stored at -80ºC for RNA sequencing
(RNAseq) analysis and the other half was stored in formalin for histopathological analyses.
AP39
AP39, synthesized in-house by Prof. Whiteman [24] (Exeter, UK), was dissolved
in dimethyl sulfoxide to achieve a 1 mM stock concentration. Two hundred microliters of
the stock was added to 1 L bags of preservation solution used for flushing, and blood used
for perfusion, to achieve a treatment concentration of 200 nM AP39 [15].
Histopathological imaging and quantification
The formalin-fixed kidney sections, including cortex and medulla, were stained
with Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) along with
Hematoxylin and Eosin (H&E) to determine the level of apoptosis and acute tubular
necrosis (ATN) respectively. TUNEL and H&E imaging was done using the Nikon
Instruments Eclipse 90i digital microscope at 10x magnification (Nikon Instruments, New
York). To quantify apoptotic injury, 10 random images of TUNEL staining were captured
per sample. The images were run through Image J v.1.50 (National Institute of Health,
USA) to determine %TUNEL+ Area, the ratio of the brown tubular area (TUNEL+) and
the total tubular area. To quantify ATN, H&E slides were scored for ATN by a blinded
renal pathologist as per the following scheme: 1= <11%, 2= 11-24%, 3= 25-45%, 4= 4675%, 5= >75%.

Statistical Analysis
GraphPad Prism 8 was used to create graphs and conduct statistical analyses.
Student’s t-test or one-way ANOVA followed by Tukey’s post-hoc test was used for
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comparisons of two or three experimental groups respectively. Statistical significance was
accepted at p<0.05.

RNASeq
Total RNA was extracted from frozen renal cortical tissues using RNEasy kits
(Qiagen, Germany) following vendor’s protocol. Total RNA samples were quantified using
the NanoDrop (Thermo Fisher Scientific, USA), and quality was assessed using the Agilent
2100 Bioanalyzer (Agilent Technologies Inc., USA) and the RNA 6000 Nano kit (Caliper
Life Sciences, USA). They were then processed using the Vazyme VAHTS Total RNAseq (H/M/R) Library Prep Kit for Illumina (Vazyme, China) which includes rRNA
reduction. Three samples (n=3) from each experimental group and one control sample from
a baseline porcine kidney with no DCD injury (CTR, n=1) were sequenced at the London
Regional Genomics Centre (Robarts Research Institute, Canada) using the Illumina
NextSeq 500 (Illumina Inc., USA).
Briefly, samples were rRNA depleted then fragmented, cDNA was synthesized,
indexed, cleaned-up and amplified via PCR. Libraries were then equimolarly pooled into
one library and size distribution was assessed on an Agilent High Sensitivity DNA
Bioanalyzer chip and quantified using the Qubit 2.0 Fluorimeter (Thermo Fisher Scientific,
USA). The library was sequenced on an Illumina NextSeq 500 as a single end run, 1x76
bp, using a High Output v2 kit (75 cycles). Fastq data files were downloaded from
BaseSpace and analyzed using Partek Flow (Partek, USA). After importation, data was
aligned to the Sus scrofa genome using STAR 2.6.1d and annotated using Ensembl v 97.
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The resulting raw gene counts were analyzed using a workflow summarized in
Fig. 3-1C. A final gene counts file was prepared after removing genes that could not be
annotated using Ensembl Biomart and genes that did not have matching human gene IDs
approved by HUGO Gene Nomenclature Committee, which is necessary for functional
enrichment analysis. Using RStudio v. 3.6.1 (Boston, USA; session info in Supplementary
Material), sample distribution mapping and principal component analysis were performed
to visualize the difference in expression profiles of samples in each group. The DESeq2
package was used to identify differentially expressed genes for the following comparisons:
SNTAP vs. SCS and SNTAP vs. SNT (alpha=0.05). Based on the protocol detailed by
Reimand et al [24], Gene Ontology (GO) annotations were found for the differentially
expressed genes using g:Profiler. These annotations were analyzed using Cytoscape v.3.7.2
to develop network enrichment maps, which facilitated the identification of certain genes
and pathways of interest for both comparisons.
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Figure 3-1 Summary of Methods. (A) Overview of experimental design. (B) Schematic of
ex vivo perfusion setup used for porcine kidney perfusion and reperfusion. (C) RNAseq
analysis workflow.
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3.4 Results
Subnormothermic perfusion with AP39-supplemented blood improves urine output
and reduces tissue injury compared to static cold storage and subnormothermic
perfusion without AP39
To investigate whether subnormothermic perfusion with AP39-supplemented
blood can improve ex vivo DCD renal graft function, porcine kidneys were assigned to 4h
of cold storage or subnormothermic perfusion with non-stressed blood at 21°C, with or
without AP39. During preservation, DCD kidneys perfused with AP39-supplemented
blood (SNTAP group) exhibited significantly higher (p<0.05) urine output than the kidneys
perfused with blood on its own (SNT group) (Fig. 3-2A). No urine output was recorded for
the static cold storage (SCS group) as those kidneys were placed on ice. The preservation
period was followed by 4h of reperfusion with stressed blood at 37°C. During reperfusion,
the SNTAP group also exhibited significantly higher urine output than the SCS group
(p<0.05) and the SNT group (p<0.01). No significant difference in urine output was
observed between the SCS and SNT group (Fig. 3-2B). Following reperfusion, the kidneys
were sagittally bivalved and formalin-fixed sections were stained with TUNEL and H&E
to determine apoptotic injury and ATN respectively (Fig. 3-3A). The SNTAP group
exhibited the lowest mean %TUNEL+ area and mean ATN score (Fig 3-3B & 3-3C). While
no statistically significant differences were found amongst the mean ATN scores (Fig. 33C), the SNTAP group exhibited significantly lower mean %TUNEL+ area than the SCS
group (p<0.05), indicating significantly lower apoptotic injury (Fig. 3B).
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Figure 3-2 Subnormothermic perfusion with AP39 improves urine output during
preservation and reperfusion. Porcine kidneys were nephrectomized after 30 minutes
of clamping to mimic DCD injury and subjected to various preservation treatments for
4h. This was followed by 4h of reperfusion with stressed autologous blood. Urine output
was collected during both perfusion periods for all groups except for the static cold
storage group, where kidneys were on ice during the 4h of preservation. (A) Total urine
output (mL) collected during 4h of preservation perfusion. (B) Total urine output (mL)
collected during 4h of reperfusion with stressed blood. Lines represent mean ± SEM.
Values in (A) were compared using student’s unpaired t-test and values in (B) were
compared using one-way ANOVA followed by Tukey’s post-hoc test. *, p<0.05. **,
p<0.01. Circles represent values for static cold storage (SCS, n = 7). Squares represent
values for subnormothermic perfusion (SNT, n = 6). Triangles represent values for
subnormothermic perfusion with 200 nM AP39 (SNTAP, n = 7).
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Figure 3-3 Subnormothermic perfusion with AP39 reduces tissue apoptosis and
acute tubular necrosis. (A) Representative TUNEL and H&E images of formalin-fixed
DCD kidney sections after 4h of preservation treatment and 4h of reperfusion. Images
were taken at10x magnification (scale bar = 100 µm). (B) Mean %TUNEL+ area as
determined by ImageJ using a ratio of TUNEL+ area (brown) to total tubular area. Each
individual data point represents the mean %TUNEL+ area of 10 random fields of view of
one porcine kidney sample. (C) ATN scores based on H&E staining. Each individual data
point represents the score assigned to one porcine kidney sample. Lines in (B) and (C)
represent mean ± SEM. Values in (B) and (C) were compared using one-way ANOVA
followed by Tukey’s post-hoc test. *, p<0.05. Circles represent values for static cold
storage (SCS, n = 7). Squares represent values for subnormothermic perfusion (SNT, n =
6). Triangles represent values for subnormothermic perfusion with 200 nM AP39
(SNTAP, n = 7).

Adding AP39 to blood during subnormothermic perfusion leads to differential prosurvival gene expression patterns compared to static cold storage and
subnormothermic perfusion without AP39.
To investigate the effect of AP39 on gene expression in this study, RNAseq was
performed on frozen porcine kidney sections collected after reperfusion. Using RStudio,
principal component analysis was performed to visualize the kidney samples in all groups
(Fig. 3-4). Using the DESeq2 package in RStudio, it was determined that 214 genes were
differentially expressed in the SNTAP group vs. the SCS group (alpha=0.05, Figure S1 in
Supplementary Material that is available online). Through network enrichment analysis,
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clusters of interest were identified based on GO annotations for the 214 genes, including
response to heat, response to stress, regulation of transcription and negative regulation of
cell death (Fig. 3-5A). Relative to the SCS group, the SNTAP group exhibited
downregulation of pro-apoptotic (BCL10) and heat shock response (HSPD1, HSPA1A)
genes, along with regulators of those pathways (BAG3, DDIT3). Additionally,
proliferation (MAPK7) and oxidative stress response (NRROS) genes were upregulated in
the SNTAP group (Fig. 3-5B). Next, it was determined that 614 genes were differentially
expressed in the SNTAP group vs. the SNT group (alpha=0.05). Clusters of interest were
identified based on GO annotations, including response to hypoxia, regulation of
transcription and response to endogenous stimulus (Fig 3-6A.) Relative to the SNT group,
several genes associated with the HIF-1α-mediated hypoxia response pathway (EGR1,
PCK1, PDK3, RGCC) were downregulated in the SNTAP group. The expression
expression of genes mediating the TGF-β pathway (SMAD3, NRROS) and HIF-1α
degradation (AJUBA) was upregulated also observed in the SNTAP group (Fig. 3-6B).
Additionally, the downregulation of pro-inflammatory (IL6, HMGB2) and pro-cell death
(HOXD8, HOXD10) genes was observed in the SNTAP group, along with upregulation of
proliferation (MAPK7) and oxidative stress response (NRROS) genes (Fig. 6C).
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Figure 3-4 Principal component analysis of r-log normalized gene counts for all
porcine kidney samples. Frozen renal cortical sections were used for RNAseq analysis.
RStudio was used to perform the principal component analysis with the full set of r-log
normalized gene counts all samples and to visualize the clustering of samples by group.
CTR, control baseline kidney with no DCD injury or preservation treatment (n=1). SCS,
static cold storage (n=3). SNT, subnormothermic perfusion (n=3). SNTAP,
subnormothermic perfusion with 200 nM AP39 (n=3). Numbers following group names
denote individual samples.

109

110

Figure 3-5 Gene expression analysis after preservation using subnormothermic
perfusion with AP39 vs. static cold storage. Frozen renal cortical sections (n=3 for each
group) were used for RNAseq analysis. Differentially expressed genes were identified
using RStudio (DESeq2, alpha = 0.05). GO annotations were found for those genes using
g:Profiler and network enrichment analysis was performed using Cytoscape. (A) Network
enrichment map showing certain nodes of interest (FDR Q value <1.0, Jaccard Overlap
combined coefficient > 0.375 with combined constant = 0.5). (B) Gene expression values
(log2FoldChange ± SEM, determined using RStudio) of certain genes of interest chosen
from three nodes of interest from the enrichment map in (A) – response to stress, negative
regulation of apoptotic process and regulation of DNA-templated transcription in response
to stress.
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Figure 3-6 Gene expression analysis after preservation using subnormothermic
perfusion with or without AP39. Frozen renal cortical sections (n=3 for each group) were
used for RNAseq analysis. Differentially expressed genes were identified using RStudio
(DESeq2, alpha = 0.05). GO annotations were found for those genes using g:Profiler and
network enrichment analysis was performed using Cytoscape. (A) Network enrichment
map showing certain nodes of interest (FDR Q value <1.0, Jaccard Overlap combined
coefficient > 0.375 with combined constant = 0.5). (B) Gene expression values
(log2FoldChange ± SEM, determined using RStudio) of all the genes in three connected
nodes from the enrichment map in (A) – response to oxygen levels, hypoxia, decreased
oxygen levels. C) Gene expression values (log2FoldChange ± SEM, determined using
RStudio) of certain genes of interest from two nodes of interest from the enrichment map
in (A) – regulation of DNA-templated transcription and response to endogenous stimulus.
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3.5 Discussion
This study shows that subnormothermic perfusion of DCD pig kidneys with
AP39-supplemented blood (SNTAP) improves the urine output, reduces tissue injury and
leads to differential pro-survival gene expression compared to static cold storage (SCS)
and subnormothermic perfusion with blood alone (SNT) in our ex vivo model of
preservation (four hours) and reperfusion (four hours).
The SNTAP group displayed a significantly higher urine output than the SNT
group during preservation and both the SNT and SCS groups during reperfusion. This is
likely due to an increase in vasodilation leading to greater renal blood flow (RBF) and
subsequent diuresis. Vasoconstriction is a critical consequence of warm ischemic injury
during DCD organ procurement and cold ischemic injury during SCS or HMP [26]. H2S
has been shown to enhance vasodilation and RBF in several studies. Xia et al. showed that
the infusion of NaHS in the intrarenal arteries of rats enhanced RBF and the glomerular
filtration rate [27]. Additionally, using a porcine model of renal transplantation, Hosgood
and Nicholson showed that the infusion of H2S ten minutes prior to and after reperfusion
improves RBF and renal function [28]. Previous studies have also shown that H2S inhibits
platelet aggregation in vitro and in vivo [29,30], which could contribute to increased blood
flow. Although AP39 has not been directly linked to RBF or platelet aggregation to date,
our RNAseq results (discussed below) suggest a potential vasodilatory mechanism that
may contribute to the significantly higher urine output of the SNTAP group.
The SNTAP group also exhibited significantly lower tissue apoptosis than the
SCS group, based on TUNEL staining. This finding was supported by the downregulation
of pro-apoptotic genes in the SNTAP group relative to the SCS group. Several studies have
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reported that AP39 reduces renal apoptosis [15, 31, 32], and it has been shown to
downregulate Bax [32], a pro-apoptotic gene in the intrinsic apoptotic pathway. This study
shows, for the first time, that AP39 may be exerting anti-apoptotic effects through
downregulating BCL10 [33,34], a pro-apoptotic regulatory gene, and DDIT3 [35], a
transcriptional regulator of endoplasmic reticulum stress-induced apoptosis. Notably, the
expression of heat shock proteins (HSPD1 and HSPA1A) and BAG3, an HSP cochaperone
[36], was downregulated in the SNTAP group. Seeing as these factors normally promote
cell survival during heat-induced stress [37,38], it is counterintuitive that they are
downregulated in the SNTAP group (21°C) compared to the SCS group (4°C). However,
the resulting anti-survival effects are likely counteracted by the downregulation of
apoptotic genes and upregulation of MAPK7, a key mediator of cell proliferation and cell
survival [39].
Interestingly, several genes associated with the HIF1α-mediated hypoxia
response, which contributes to acute kidney injury and renal IRI [40], were downregulated
in the SNTAP group relative to the SNT group. The downregulation of PCK1 [41] and
PDK3, metabolic targets activated by HIF1α [42], may help with managing the metabolic
demand at 21°C that is not being met with metabolites, thereby mitigating tissue injury.
The downregulation of RGCC, a negative regulator of HIF1α-mediated angiogenesis [43],
and EGR1, a negative coregulator of erythropoietin-receptor expression [44], likely
promotes vascularization. This may contribute to the improved urine output of the SNTAP
group through improving the RBF. The upregulation of AJUBA, a mediator of HIF1α
degradation [45], likely helps to balance the positive and negative effects of HIF1α and
other genes associated with it. Additionally, the SNTAP group exhibited downregulation
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of the pro-apoptotic genes (HOXD8 and HOXD10) [46,47], which could further explain
the lower tissue apoptosis in the SNTAP group.
The SNTAP group also exhibited upregulation of MAPK7 and NRROS
compared to both the SCS and SNT groups. AP39 has been shown to reduce reactive
oxygen species (ROS) levels in vitro [15,32]. The downregulation of NRROS, which
negatively regulates ROS production [48] and activates TGF-β1 [49,50], could underlie
the antioxidant and protective responses observed by previous studies on AP39.
Additionally, the downregulation of IL6 was observed in the SNTAP group relative to the
SNT group, which matches the findings of a previous study looking at the effect of AP39
in myocardial IRI [32]. IL6 is a key proinflammatory cytokine in the progression of acute
kidney injury [51], and its downregulation by AP39 may contribute to the improved
outcomes of the SNTAP group compared to the SNT group.
There are two limitations to the perfusion model used in this study. Firstly, the
perfusion times used are relatively short. However, the four-hour duration was deemed
appropriate, because this was the first time that our novel approach towards organ
preservation was attempted on large mammalian kidneys, and hence, we wanted to prove
its feasibility. Further testing using longer periods of preservation and reperfusion will be
necessary for clinical translation. Secondly, the limitation of having only one organ
perfusion pump due to financial constraints required us to place the two kidneys on the
same circuit during the reperfusion phase; however, the urine output from each kidney was
collected separately. Perfusing both kidneys on separate pumps would have prevented their
metabolites from pooling into a shared blood reservoir. Despite this limitation, the SNTAP
group exhibited significantly higher urine output during reperfusion and a significantly
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lower TUNEL score than the SCS group. This suggests that if we had reperfused the
kidneys on two separate pumps, our positive findings would have been accentuated to a
greater extent, which further supports the use of our novel approach.
While the number of samples we could perform RNAseq testing on was limited
by the cost, the consistency in gene expression across the samples in most groups facilitated
a reliable analysis within the constraints of this limitation. Additionally, the findings of our
study were strengthened by the approach of clamping the renal pedicle to mimic a DCD
injury. Inducing the complete cessation of the RBF via clamping mimics an extreme
clinical DCD scenario where no oxygen is supplied to the kidneys. Thus, the positive
outcomes observed in this study are more likely to translate to and be accentuated in real
clinical DCD scenarios where there is a more gradual cessation of blood flow as cardiac
death occurs. Evidently, further in vitro research is needed to confirm the mechanisms
underlying AP39′s protective effects. Future studies using in vivo models of renal
transplantation and clinically approved H2S donors are also needed to support the findings
of this study.
In conclusion, this study demonstrates that subnormothermic perfusion with
AP39-supplemented blood can improve ex vivo DCD porcine renal graft function. We
postulate that the subnormothermic temperature allows for maintenance of the vasculature,
unlike static cold storage, with a metabolic demand that is lower than normal due to the
deviation from the physiological temperature (37°C). The presence of H2S helps mitigate
some of the negative consequences of being unable to meet the metabolic demand at 21°C
in a nutrient-deficient environment, such as inflammation, ROS and apoptosis. Overall,
this study adds to the growing body of literature that supports the use of subnormothermic
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temperatures and H2S in organ preservation to improve DCD renal graft outcomes. These
strategies could facilitate the use of more marginal grafts, which could increase the pool of
transplantable organs.

3.6 Supplementary Material
Supplementary Figure S1
Available online at https://www.mdpi.com/2218-273X/11/3/446/s1
Figure S1: Heatmap of the differential gene expression analysis after preservation
using subnormothermic perfusion with AP39 vs. static cold storage. Porcine kidneys
were nephrectomized after 30 min of clamping to mimic DCD injury and subjected to
subnormothermic perfusion with AP39 (SNTAP) or static cold storage (SCS) for 4 h. This
was followed by 4 h of reperfusion with stressed autologous blood. Frozen renal cortical
sections (n= 3 for each group) were used for the RNAseq analysis. Differentially expressed
genes were identified using RStudio (DESeq2,alpha = 0.05), and a heap map was
generated. CTR, control baseline kidney with no DCD injury or preservation treatment
(n=1).
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4.1 Abstract
The use of blood for normothermic and subnormothermic kidney preservation
hinders the translation of these approaches and promising therapeutics. This study
evaluates whether adding hydrogen sulfide donor AP39 to Hemopure, a blood substitute,
during subnormothermic perfusion improves kidney outcomes. After 30 minutes of renal
pedicle clamping, porcine kidneys were treated to 4h of static cold storage (SCS-4°C) or
subnormothermic perfusion at 21°C with Hemopure (H-21°C), Hemopure + 200nM AP39
(H200nM-21°C) or Hemopure + 1µM AP39 (H1µM-21°C). Then, kidneys were reperfused
with Hemopure at 37°C for 4h with metabolic support. Perfusate composition, tissue
oxygenation, urinalysis and histopathology were analyzed. During preservation, the
H200nM-21°C group exhibited significantly higher urine output than the other groups and
significantly higher tissue oxygenation than the H1µM-21°C group at 1h and 2h. During
reperfusion, the H200nM-21°C group exhibited significantly higher urine output and lower
urine protein than the other groups. Additionally, the H200nM-21°C group exhibited
higher perfusate pO2 levels than the other groups and significantly lower apoptotic injury
than the H-21°C and the H1µM-21°C groups. Thus, subnormothermic perfusion at 21°C
with Hemopure + 200nM AP39 improves renal outcomes. Additionally, our novel bloodfree model of ex vivo kidney preservation and reperfusion could be useful for studying
other therapeutics.
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4.2 Introduction
Renal transplantation is preferred treatment for end-stage renal disease because it
improves long-term survival and quality of life compared to hemodialysis.1–3 However,
there is a critical shortage of donor kidneys across the globe due to the increasing need for
kidney transplants. In Canada, the prevalence of end-stage renal disease has risen by 33%
between 2010 and 2019.4 Despite the 1,648 adult kidney transplants that were performed
in 2019, 3,261 individuals remained on the waiting list.5 To meet the rising demand,
kidneys from marginal donors are being used more frequently. While donation after
neurological death does not impact organ health, donation after cardiac death (DCD) leads
to warm ischemic injury as blood flow decreases and the heart stops. This is of concern
because DCD kidneys are being transplanted more frequently and often lead to poorer
patient outcomes compared to kidneys from other donors.6 Additionally, clinical cold
preservation methods (4°C), such as static cold storage (SCS), exacerbate DCD kidney
outcomes due to the combination of cold and warm ischemic injury.7–9
Several strategies have been explored to improve cold preservation methods, such
as the addition of hydrogen sulfide (H2S), a gasotransmitter with cytoprotective properties,
to preservation solutions.10–12 Our group and others have previously shown that adding
nanomolar concentrations of H2S donor AP39 to cold preservation solution improves renal
and cardiac graft outcomes.11,13 Additionally, there is rising interest in alternatives to cold
preservation that employ normothermic (36-37°C) and subnormothermic (15-35°C)
temperatures.14 Several porcine and discarded human kidney studies have shown that
normothermic and subnormothermic machine perfusion improve DCD renal graft
outcomes compared to SCS on ice.15–20 However, a major challenge in this context is the
need for oxygenation and nutrients to meet the metabolic demand of the kidney at these
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higher temperatures. Previous studies have primarily used erythrocyte-based solutions or
autologous whole blood for this purpose16,18,21, but the use of blood is a challenge for the
clinical translation of these approaches. Pervasive shortages of banked blood and the
challenges associated with obtaining blood from DCD donors limit the availability of blood
for ex vivo kidney preservation.
The use of blood substitutes, especially hemoglobin-based oxygen carriers
(HBOC), can solve the problem of oxygenation and circumvent the need for blood in the
context of normothermic and subnormothermic preservation. One promising candidate is
Hemopure (also known as HBOC-201), which is made of highly purified bovine
hemoglobin.22,23 Clinically, Hemopure is used to treat anemia in patients who cannot
receive blood transfusions.24,25 However, several recent studies have shown that ex vivo
kidney preservation with Hemopure can improve renal graft outcomes. In 2019, Aburawi
et al. reported that normothermic perfusion (37°C) of discarded human kidneys with
Hemopure vs. packed red blood cells led to comparable outcomes.26 Subsequently a recent
study by our center has shown that subnormothermic perfusion (22°C) of DCD porcine
kidneys with Hemopure vs. whole blood exhibited similar outcomes, which further
confirms the feasibility of Hemopure for blood-free renal graft preservation.19
While recent evidence supports the use of Hemopure for kidney preservation, it’s
potential as a platform to deliver therapeutics that could further enhance renal graft
outcomes remains unexplored. We have previously shown that adding H2S donor AP39 to
University of Wisconsin (UW) solution, a preservation solution that is commonly used for
SCS, made it suitable for subnormothermic preservation.27 Additionally, we have shown
that subnormothermic perfusion (21°C) of DCD porcine kidneys with AP39-supplemented
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whole blood improves renal graft outcomes and reduces tissue injury using an ex vivo
model of blood-based preservation and reperfusion.20 In this study, we investigate whether
subnormothermic perfusion at 21°C with AP39-supplemented Hemopure improves DCD
porcine renal graft outcomes compared to SCS and subnormothermic perfusion with
Hemopure alone. To evaluate this aim, we use a novel blood-free model of ex vivo
preservation and reperfusion. In this model, after 4 hours of blood-free preservation, all
kidneys are reperfused (37°C) for 4 hours with Hemopure, supplemented with a diuretic
and metabolic support, to mimic the post-transplant milieu.

4.3 Materials and Methods
Animal care and surgery
Yorkshire pigs (60-70kg), purchased from a regional farm, were tranquilized and
routinely prepped for surgery. A midline incision was used to expose the kidneys.
Following intravenous infusion of 10000 U of heparin, the renal pedicles were clamped in
situ for 30 minutes to induce warm ischemia and mimic DCD injury. The complete
cessation of renal blood flow replicates an extreme clinical DCD scenario where no oxygen
is being supplied to the kidneys. This approach has been used in many other studies within
the field and previous studies by our center. During the clamping period, the ureters and
arteries were cannulated to facilitate ex vivo perfusion and urine collection. Subsequently,
both kidneys were nephrectomized and the donor animal was euthanized. Surgeries were
performed by transplant fellows at University Hospital, London, Canada. All procedures
were approved by University of Western Ontario’s Animal Use Committee (Animal Use
Protocol 2018-090).
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Ex vivo perfusion setup
The ex vivo perfusion setup used in this study is identical to the setup used in
previous studies18–20 by our center (Fig. 4-1). Mean perfusion pressure was maintained at
60 mmHg through adjusting the flow of the perfusate. Fresh perfusate (1L) was prepared
for preservation and reperfusion by mixing 250 mL of Hemopure (generously provided by
HbO2 Therapeutics, USA) with 750 mL of PlasmaLyte solution (Baxter International Inc.,
USA). The perfusate was supplemented with the following: heparin (5000 U), sodium
bicarbonate (8.4%, 10mL) and Ancef (1g). Pairs of kidneys were perfused together due to
having a single pulsatile pump. However, each kidney was considered as one replicate
because its urine output was collected individually.

Figure 4-1 The ex vivo pulsatile perfusion setup used for blood-free preservation and
reperfusion. A pair of kidneys, placed in the perfusion cassette, are receiving externally
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oxygenated perfusate through their arteries. Their ureters are connected to urine
collection bags to measure and collect each kidney’s urine output individually. A waterbased heat exchanger is connected to the perfusate oxygenator to control the temperature
of the perfusate. The image specifically reflects the setup for reperfusion due to presence
of dextrose and insulin drips.
Blood-free preservation treatments
Pairs of kidneys were assigned to one of four treatment groups (Fig. 4-2). The first
group of kidneys were flushed with and stored in Histidine-Tryptophan-Ketoglutarate
(HTK) solution (Custodiol®, USA) on ice for 4h (SCS-4°C), which reflects the clinical
standard of care. The second group of kidneys were flushed with HTK solution and treated
to 4h of subnormothermic perfusion at 21°C with Hemopure (H-21°C). The third group of
kidneys were flushed with HTK solution + 200 nM AP39 and treated to 4h of
subnormothermic perfusion at 21°C with Hemopure + 200 nM AP39 (H200nM-21°C). The
fourth group of kidneys were flushed with HTK solution + 1 µM AP39 and treated to 4h
of subnormothermic perfusion at 21°C with Hemopure + 1 µM AP39 (H1µM-21°C). For
the three preservation treatments involving subnormothermic perfusion, urine output was
recorded hourly and the volume loss was replaced with the addition of PlasmaLyte.
Additionally, tissue oxygenation was measured hourly using the InSpectra StO2 Spot
Check Tissue Perfusion Monitor (Hutchinson Technology, USA).
Blood-free reperfusion protocol
Following 4h of preservation, kidneys were reperfused for 4h using our novel
blood-free reperfusion model (Fig. 4-2). Due to budget constraints, the same perfusion
cassettes were used throughout preservation and reperfusion. To prevent the mixing of the
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perfusates from both halves of the experiment, the perfusion circuit was drained and
flushed with 2 L of saline between preservation and reperfusion. After the saline flush, 1 L
of fresh Hemopure/PlasmaLyte solution was added for reperfusion and the temperature
was set to 37°C. At the start of reperfusion, 4 g of mannitol was added to the perfusate to
mimic the post-operative administration of a diuretic to renal transplant recipients.
Additionally, we implemented 5% dextrose and insulin drips to provide metabolic support
to the kidneys, maintaining a perfusate glucose concentration of ~150 mg/dL.
During reperfusion, urine samples were collected, and urine output was recorded
hourly. The volume lost was replaced with the addition of PlasmaLyte. Tissue oxygenation
was measured hourly as described earlier. Additionally, perfusate parameters (pH, pO2,
and lactate) were measured using the iSTAT Handheld Blood Analyzer (Abbott
Laboratories, USA) to allow for relative comparison between groups. Sodium bicarbonate
was injected as needed to adjust perfusate pH. After 4h of reperfusion, kidney sections
(cortex and medulla) were cut and stored in formalin for histopathological analyses.
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Figure 4-2 Summary of the preservation treatment groups and methodology.
AP39
AP39, synthesized in-house by Prof. Whiteman28, was dissolved in dimethyl
sulfoxide to achieve a 1mM stock concentration. To achieve a treatment concentration of
200 nM AP39, 200 µL of the stock was added to 1 L of preservation solution and perfusate.
Similarly, for a concentration of 1 µM AP39, 1 mL of the stock was added to 1 L of
preservation solution and perfusate. The doses were chosen based on previous studies by
our group.
Urinalysis
Most of the urine samples collected were heavily pigmented, due to the presence of
hemoglobin from the Hemopure, which prevented the use of conventional urinalysis
methods. A 1:3 dilution of urine in Hemoglobind (Biotech Support Group, USA) allowed
us to obtain clearer urine samples after 10 minutes of vigorous shaking and centrifugation
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at 12,000g. Urine protein and creatinine levels were analyzed using the IDEXX Urine
Analyzer (IDEXX Laboratories, USA), but creatinine values remained undetectable.
Histopathology imaging and scoring
Formalin-fixed kidney sections, including cortex and medulla, were embedded in
paraffin and mounted onto microscope slides. The sections were stained with Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and Hematoxylin and
Eosin (H&E) to determine the level of apoptosis and acute tubular necrosis respectively.
TUNEL and H&E imaging was done using the Nikon Instruments Eclipse 90i digital
microscope at 10x magnification (Nikon Instruments, New York). Both sets of slides were
scored by a blinded renal pathologist as per the following scheme: 1= <11%, 2= 11-24%,
3= 25-45%, 4= 46-75%, 5= >75%.
Statistical analyses
GraphPad Prism 9 was used to create graphs and conduct statistical analyses. Oneway or two-way ANOVA followed by Tukey’s post-hoc test was used for comparisons of
three or more experimental groups. Statistical significance was accepted at p<0.05.
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4.4 Results
Subnormothermic perfusion with Hemopure + 200nM AP39 at 21°C improves gross
kidney morphology and perfusate pO2 levels during blood-free reperfusion
Kidneys were imaged prior to preservation (after flushing) and at the end of
reperfusion to evaluate differences in gross morphology (Fig. 4-3). The images taken prior
to preservation show that the kidneys in each group had similar gross morphology and were
thoroughly flushed following the induction of warm ischemia, which is reflected by the
pale colour. At the end of reperfusion, the H200nM-21°C kidneys looked the reddest,
which is an indicator of consistent perfusion and overall organ health. On the other hand,
the H1µM-21°C kidneys looked much darker than the other groups at the end of
reperfusion, which is an indicator of thrombosis and tissue injury (Fig. 4-3). Additionally,
perfusate samples were analyzed hourly during reperfusion to evaluate relative changes in
pO2, pH and lactate levels (Fig. 4-4, Table 2). The H200nM-21°C group exhibited higher
perfusate pO2 levels than the SCS-4°C, H-21°C and H1µM-21°C groups throughout the
reperfusion period. Additionally, the perfusate pO2 levels stayed relatively consistent over
time for each group (Fig. 4-4A). The H1µM-21°C group exhibited higher perfusate pH
than the other three groups throughout the reperfusion period. Apart from the elevated pH
of this group and the high variability at the 1h timepoint, perfusate pH was maintained
within the range of 7.1 to 7.4. Interestingly, perfusate pH decreased over time for each
group (Fig. 4-4B). Furthermore, all four groups exhibited comparable increases in lactate
levels throughout the reperfusion period, which contributes to the decrease in perfusate pH
described earlier (Fig. 4-4B). None of the differences in perfusate parameter levels were
statistically significant.
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Figure 4-3 Gross morphology of the kidneys prior to preservation and at the end of
reperfusion. Images were taken prior to perfusion to document the consistent flushing of
the kidneys following the induction of warm ischemia. Images were taken at the end of
reperfusion to document the gross morphology of kidneys by the end of the experiment.
One pair of representative images were chosen for each preservation treatment group.
Treatment groups: SCS-4°C, static cold storage on ice at 4°C. H-21°C, perfusion with
Hemopure at 21°C. H200nM-21°C, perfusion with Hemopure + 200 nM Ap39 at 21°C.
H1µM-21°C, perfusion with Hemopure + 1µM Ap39 at 21°C.

140

Figure 4-4 Perfusate parameters during blood-free reperfusion. (A) pO2 (mmHg), (B)
pH and (C) Lactate (mmol/L) during blood-free reperfusion. Since pairs of kidneys were
reperfused with shared perfusate, singular readings were obtained at each timepoint for
each pair of kidneys. The iSTAT Analyzer was unable to detect tissue oxygenation for one
pair of kidneys (n=1) in the H1µM-21°C group. Individual points on each graph represent
the mean value at a specific timepoint for pairs of kidneys within a single treatment group.
SEM values are not presented on the graphs to allow for clear visualization of trends
without overlapping error bars. Mean ± SEM are listed in Table 2. After a GeisserGreenhouse correction, values were compared using repeated measures two-way ANOVA
followed by Tukey’s post-hoc test and no significant differences were found. Treatment
groups: SCS-4°C, static cold storage on ice at 4°C (n=3). H-21°C, perfusion with
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Hemopure at 21°C (n=3). H200nM-21°C, perfusion with Hemopure + 200nM AP39 at
21°C (n=3). H1µM-21°C, perfusion with Hemopure + 1µM AP39 at 21°C (n=2).
Table 2- Mean perfusate parameters ± SEM during blood-free preservation and
reperfusion.

Group (n)
SCS-4°C
(n = 3)
H-21°C
(n = 3)
H200nM-21°C
(n = 3)
H1µM-21°C
(n = 2)

Group (n)
SCS-4°C
(n = 3)
H-21°C
(n = 3)
H200nM-21°C
(n = 3)
H1µM-21°C
(n = 2)

Group (n)
SCS-4°C
(n = 3)
H-21°C
(n = 3)
H200nM-21°C
(n = 3)
H1µM-21°C
(n = 2)

1h
227.00 ± 6.43

pO2 (mmHg)
Reperfusion Timepoint
2h
3h
231.00 ± 15.04 231.00 ± 9.644

4h
221.33 ± 9.493

215.66 ± 3.71

221.33 ± 9.59

224.33 ± 6.17

221.33 ± 3.28

242.66 ± 14.19

242.66 ± 18.97

238.66 ± 5.78

241.00 ± 15.50

213.00 ± 13.00

214.00 ± 13.00

215.50 ± 5.50

212.00 ± 8.00

1h
7.40 ± 0.11

pH
Reperfusion Timepoint
2h
3h
7.27 ± 0.09
7.17 ± 0.08

4h
7.05 ± 0.09

7.67 ± 0.13

7.35 ± 0.13

7.49 ± 0.12

7.38 ± 0.10

7.17 ± 0.04

7.29 ± 0.23

7.24 ± 0.11

7.13 ± 0.03

7.84 ± 0.10

7.71 ± 0.09

7.56 ± 0.08

7.44 ± 0.05

1h
4.39 ± 0.59

Lactate (mmol/L)
Reperfusion Timepoint
2h
3h
6.51 ± 0.84
8.22 ± 0.69

4h
9.54 ± 0.68

3.34 ± 0.35

4.84 ± 0.81

6.49 ± 0.99

8.35 ± 1.36

3.78 ± 0.12

5.73 ± 0.12

7.023 ± 0.68

9.64 ± 1.02

2.90 ± 0.90

5.79 ± 0.79

8.29 ± 0.29

10.69 ± 0.48

Note: SCS-4°C, static cold storage on ice at 4°C. H-21°C, perfusion with Hemopure at
21°C. H200nM-21°C, perfusion with Hemopure + 200 nM Ap39 at 21°C. H1µM-21°C,
perfusion with Hemopure + 1µM Ap39 at 21°C.
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Subnormothermic perfusion with Hemopure + 200nM AP39 at 21°C improves tissue
oxygenation during blood-free preservation
To evaluate the impact of the treatments on organ perfusion, tissue oxygenation
was measured hourly during preservation and reperfusion (Fig. 4-5, Table 3). During
preservation, the H200nM-21°C group exhibited higher tissue oxygenation at all
timepoints relative to the H-21°C and H1µM-21°C groups. Statistically, the H200nM-21°C
group exhibited significantly higher tissue oxygenation than the H1µM-21°C group at the
1h and 2h timepoints during preservation (Fig. 4-5A). During reperfusion, the H-21°C
group exhibited the highest tissue oxygenation, followed by the H200nM-21°C group. The
SCS-4°C and the H1µM-21°C groups exhibited similar tissue oxygenation trends and the
levels for both groups were lower than the other two groups at the 2h, 3h and 4h timepoints
(Fig. 4-5B). Interestingly, the tissue oxygenation levels for each group stayed relatively
consistent throughout the preservation period (Fig. 4-5A), while the levels gradually
increased for each group throughout the reperfusion period (Fig. 4-5B).
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Figure 4-5 Mean tissue oxygenation during blood-free preservation and reperfusion.
(A) Tissue oxygenation (%) during 4h of blood-free preservation with Hemopure (H-21°C,
n=5), Hemopure + 200nM AP39 (H200nM-21°C, n=5) or Hemopure + 1µM AP39
(H1µM-21°C, n=4). No values were recorded for the static cold storage (SCS-4°C, n=6)
group as the kidneys were on ice. (B) Tissue oxygenation (%) during 4h of blood-free
reperfusion with Hemopure and metabolic support at 37°C. The InSpectra StO2 Spot
Check Tissue Perfusion Monitor was unable to detect tissue oxygenation for one pair of
kidneys (n=2) in the H1µM-21°C group. Individual points on each graph represent the
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mean tissue oxygenation (%) level at a specific timepoint for individual kidneys within a
single treatment group. SEM values are not presented on the graphs to allow for clear
visualization of trends without overlapping error bars. Mean ± SEM are listed in Table 3.
After a Geisser-Greenhouse correction, values were compared using repeated measures
two-way ANOVA followed by Tukey’s post-hoc test. *, p<0.05 for H200nM-21°C
compared to H1µM-21°C.
Table 3- Mean tissue oxygenation (%) ± SEM (%) during blood-free preservation
and reperfusion.

Group (n)
1h
SCS-4°C
(n=6)
H-21°C
(n = 5)
H200nM-21°C
(n = 5)
H1µM-21°C
(n = 4)
Group (n)
SCS-4°C
(n = 6)
H-21°C
(n = 5)
H200nM-21°C
(n = 5)
H1µM-21°C
(n = 4)

Mean Tissue Oxygenation (%) ± SEM (%)
Preservation Timepoint
2h
3h
No data collected while kidneys were on ice

4h

65.37 ± 1.65

63.86 ± 1.94

63.11 ± 2.04

63.06 ± 2.02

68.04 ± 1.02

69.29 ± 1.76

67.62 ± 3.36

68.43 ± 4.10

61.93 ± 1.42

60.04 ± 1.78

60.75± 2.02

61.29 ± 1.21

1h
67.12 ± 0.88

Reperfusion Timepoint
2h
3h
68.12 ± 0.47
73.29 ± 0.40

4h
77.57 ± 0.24

68.31 ± 6.20

77.29 ± 6.15

81.80 ± 5.55

84.71 ± 5.52

66.35 ± 1.91

72.90 ± 2.34

77.73 ± 2.62

79.00 ± 2.44

62.61 ± 0.82

68.46 ± 0.89

72.46 ± 0.91

76.57 ± 2.91

Note- Bolded values in each column were significantly different relative to each other
(p<0.05) as per repeated measures Two-way ANOVA and Tukey’s post-hoc test after a
Geisser-Greenhouse correction. SCS-4°C, static cold storage on ice at 4°C. H-21°C,
perfusion with Hemopure at 21°C. H200nM-21°C, perfusion with Hemopure + 200 nM
Ap39 at 21°C. H1µM-21°C, perfusion with Hemopure + 1µM Ap39 at 21°C.
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Subnormothermic perfusion with Hemopure + 200nM AP39 at 21°C improves kidney
function during blood-free preservation and reperfusion
To evaluate kidney function, urine output was measured during both halves of the
experiment and urinalysis was performed (Fig. 6). During preservation, the H200nM-21°C
group exhibited significantly higher urine output than the H-21°C and H1µM-21°C groups
(Fig. 4-6A). This trend continued during reperfusion as the H200nM-21°C group exhibited
significantly higher urine output than the SCS-4°C, H-21°C and H1µM-21°C groups (Fig.
4-6B). Since no urine was collected for the SCS-4°C group during preservation as the
kidneys were on ice, urine samples collected at the 1h and 4h timepoints during reperfusion
were analyzed to compare all four groups. Samples collected from the H200nM-21°C
group at the 1h timepoint exhibited lower urine protein levels than all the other groups;
however, only the difference between the H-21°C and the H200nM-21°C group was
statistically significant (Fig. 4-6C). This trend continued as the samples collected from the
H200nM-21°C group at the 4h timepoint also exhibited lower urine protein levels than all
the other groups. However, no statistically significant differences were found between
urine protein levels at the 4h timepoint (Fig. 4-6D).
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Figure 4-6 Urine parameters during blood-free preservation and reperfusion. (A)
Total urine output (mL) during 4h of blood-free preservation with Hemopure (H-21°C,
n=5), Hemopure + 200nM AP39 (H200nM-21°C, n=5) or Hemopure + 1µM AP39
(H1µM-21°C, n=6). No values were recorded for the static cold storage (SCS-4°C, n=6)
group as the kidneys were on ice. (B) Total urine output (mL) during 4h of blood-free
reperfusion with Hemopure and metabolic support at 37°C. (C) Urine protein (g/L) levels
in urine samples collected 1h after the start of reperfusion. (D) Urine protein (g/L) levels
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in urine samples collected in the final hour (4h) of reperfusion. An outlier was excluded
from the H1µM-21°C group in (D). Individual points on each graph reflect values for
individual kidneys and lines represent the mean ± SEM. Values were compared using oneway ANOVA followed by Tukey’s post-hoc test. *, p<0.05. **, p<0.01. ***, p<0.001.
****, p<0.0001.

Subnormothermic perfusion with Hemopure + 200nM AP39 at 21°C reduces
apoptotic kidney injury following blood-free preservation and reperfusion
To evaluate apoptotic tissue injury, kidney sections were stained with TUNEL (Fig.
4-7A) and scored by a blinded renal pathologist (Fig. 4-7B). The H200nM-21°C group
received lower TUNEL scores than all the other groups, which indicates that this group
exhibited the lowest apoptotic injury. Statistically, the TUNEL scores of the H200nM21°C group were significantly lower than the scores of the H-21°C and H1µM-21°C
groups. Although the TUNEL scores of the H200nM-21°C group were also lower than the
scores of the SCS-4°C group, the difference was not statistically significant (Fig. 4-7B).
To evaluate acute tubular necrosis (ATN), kidney sections were stained with H&E (Fig. 48A) and scored by a blinded renal pathologist (Fig. 4-8B). The SCS-4°C, H-21°C and
H200nM-21°C groups received similar ATN scores. However, the ATN scores of the
H1µM-21°C group were significantly higher than the scores of the H-21°C and H200nM21°C groups, which indicates that this group exhibited more severe ATN. Although the
ATN scores of the H1µM-21°C group were also higher than the scores of the SCS-4°C
group, the difference was not statistically significant (Fig. 4-8B).
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Figure 4-7 Apoptotic tissue injury following blood-free preservation and reperfusion.
(A) Representative TUNEL images of formalin-fixed kidney sections after 4h of bloodfree preservation treatment and 4h of blood-free reperfusion. Images were taken at 10x
magnification (scale bar = 100 µm). Black arrows represent apoptotic cells. (B) TUNEL
scores assigned by a blinded renal pathologist (1= <11%, 2= 11-24%, 3= 25-45%, 4= 4675%, 5= >75%). Each individual data point represents the score assigned to one porcine
kidney sample. Lines represent mean ± SEM. Values were compared using one-way
ANOVA followed by Tukey’s post-hoc test. *, p<0.05. **, p<0.01. Treatment groups:
SCS-4°C, static cold storage on ice at 4°C (n=6). H-21°C, perfusion with Hemopure at
21°C (n=5). H200nM-21°C, perfusion with Hemopure + 200nM AP39 at 21°C (n=5).
H1µM-21°C, perfusion with Hemopure + 1µM AP39 at 21°C (n=6).
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Figure 4-8 Acute tubular necrosis following blood-free preservation and reperfusion.
(A) Representative H&E images of formalin-fixed kidney sections after 4h of blood-free
preservation treatment and 4h of blood-free reperfusion. Images were taken at10x
magnification (scale bar = 100 µm). Black arrows indicate areas of acute tubular injury,
including tubular cell sloughing, epithelial flattening and tubular dilation. (B) Acute tubular
necrosis (ATN) scores assigned by a blinded renal pathologist (1= <11%, 2= 11-24%, 3=
25-45%, 4= 46-75%, 5= >75%). Each individual data point represents the score assigned
to one porcine kidney sample. Lines represent mean ± SEM. Values were compared using
one-way ANOVA followed by Tukey’s post-hoc test. *, p<0.05. Treatment groups: SCS4°C, static cold storage on ice at 4°C (n=6). H-21°C, perfusion with Hemopure at 21°C
(n=5). H200nM-21°C, perfusion with Hemopure + 200nM AP39 at 21°C (n=5). H1µM21°C, perfusion with Hemopure + 1µM AP39 at 21°C (n=6).
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4.5 Discussion
This study establishes a novel blood-free model of ex vivo kidney preservation and
reperfusion using Hemopure, a hemoglobin-based oxygen carrier that serves as a blood
substitute. Using this model, we show that subnormothermic perfusion of DCD pig kidneys
at 21°C with AP39-supplemented Hemopure improves graft function and reduces tissue
injury compared to static cold storage and subnormothermic perfusion with Hemopure
alone.
The primary finding of this study is that the H200nM-21°C group displayed
significantly improved or comparable outcomes relative to the SCS-4°C group, which
reflects the clinical standard of care for kidney preservation. Importantly, the H200nM21°C group exhibited significantly higher urine output than the SCS-4°C group during
reperfusion. The immediacy of post-operative urine output is a critical renal transplant
outcome as it determines whether dialysis is needed to address delayed graft function. In
2018, Hosgood et al. successfully transplanted declined human kidneys after assessing
several parameters, including urine output, during 1h of ex vivo normothermic perfusion.29
The five kidneys that were transplanted based on their criteria had higher urine outputs
than those that were not transplanted and only one kidney exhibited delayed graft function.
Although additional research is needed to validate their method, their findings suggest that
ex vivo urine output can be used to determine if a kidney is suitable for transplant. While
we have yet to evaluate our novel preservation approach using declined human kidneys,
the difference in urine output observed in this study has promising implications.
In addition to showing that our novel approach matches the clinical standard of
care, this study strengthens the evidence supporting the use of 200 nM AP39 in kidney
preservation. We have previously shown that prolonged SCS in UW + 200 nM AP39
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improves recipient outcomes in an in vivo model of murine renal transplantation.11
Additionally, this dose has shown efficacy in our recent studies on the use of AP39 in
subnormothermic kidney preservation.20,27 From a mechanistic standpoint, our in vitro
research has shown that 200 nM AP39 preserves mitochondrial membrane potential along
with reducing apoptosis and the production of reactive oxygen species.11 Furthermore, the
RNA sequencing analysis of DCD pig kidneys preserved with AP39-supplemented blood
in our previous study implicated the downregulation of pro-apoptotic and hypoxia response
genes as potential mechanisms underlying the protective effects of AP39.20 The inclusion
of the H1µM-21°C group in this study is our first attempt at using a higher dose of AP39
in a mammalian model. The 1 µM dose was chosen based on its efficacy in a frostbite
model (unpublished). Seeing as the H1µM-21°C group exhibited significantly lower urine
output and significantly higher tissue injury than the H200nM-21°C group, this study
further supports the use of a low dose of (200 nM) AP39. Interestingly, the differences in
the outcomes of the H-21°C and SCS-4°C groups do not match expectations and showed
comparable outcomes. A previous study conducted at our center showed that
subnormothermic perfusion with Hemopure significantly improved urine output and
reduced tissue injury compared to SCS.19
One of the focal points of this study is our novel blood-free model of preservation
and reperfusion. While Hemopure has been used for normothermic and subnormothermic
kidney preservation before,19,20,26 we are the first to use it consecutively for
subnormothermic preservation at 21°C and reperfusion at 37°C. With the efficacy of AP39suppplemented Hemopure during preservation, we have circumvented a major roadblock
to translation – the acquisition of human blood for DCD kidney preservation. Additionally,
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we used Hemopure for reperfusion to establish a completely blood-free platform for
evaluating targeted therapies. While no standard perfusate composition or perfusion
protocol exists, the supplements added to the Hemopure/PlasmaLyte mixture in this study
align with those used in previous studies reviewed by Elliot et al.30
On the other hand, our novel perfusion model has several limitations. Although we
used Hemopure to establish a blood-free model of preservation and reperfusion, the lack
of white blood cells in our perfusate largely excludes the inflammatory component of
reperfusion with blood. Additionally, the pigmented nature of Hemopure, due to the
hemoglobin, prevented the use of colorimetric and fluorescent assays to detect
inflammatory markers in the perfusate. Furthermore, pairs of kidneys were connected to
the same circuit and perfused using a shared Hemopure reservoir due to the limitation of
having only one organ perfusion pump. Although we collected urine output separately for
each kidney, the perfusate parameter readings were less robust, as only one reading was
obtained due to the perfusate being shared by pairs of kidneys. Moreover, we were unable
to detect perfusate parameters (pO2, pH and Lactate) with our iSTAT analysis platform
since it was designed for use with blood (not Hemopure) at normothermic temperatures
rather than subnormothermic temperatures. Our attempt to use the IDEXX analysis
platform to detect perfusate levels during preservation also failed. Moreover, our study
lacks a number of controls such as cold or subnormothermic perfusion group without
Hemopure. This is because the high cost (CAD 5000/pig experiment) limits the number of
groups we could evaluate. Thus, we designed our study around the premise of comparing
the outcomes of our novel approach to that of SCS, which is the clinical standard of care,
and perfusion with Hemopure alone, which is the control for the effects of temperature and
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oxygenated perfusion. Lastly, while perfusion was kept at constant pressure by adjusting
the flow, we are unable to report flow data.
As mentioned above, this study advances our previous findings that showed the
efficacy of preserving DCD pig kidneys using subnormothermic perfusion at 21°C with
AP39-supplemented blood.20 There is some overlap in the strengths and limitations of both
studies due to the overlap in methodology. Per our previous study, we induced warm
ischemic injury by clamping the renal pedicle. This approach mimics an extreme clinical
DCD scenario where no oxygen is supplied to the kidneys due to a complete cessation of
blood flow. Thus, the positive outcomes observed would likely be heightened in real
clinical DCD scenarios, where there is a gradual reduction in blood flow as the donor’s
heart stops pumping blood. Additionally, the 4h duration of the preservation and
reperfusion periods is relatively short. However, this was deemed appropriate for
establishing a novel model and for facilitating comparisons to our previous study.
While no mechanistic advances were made, our methodology has improved with
the addition of new approaches to evaluate urine protein levels and tissue oxygenation in
real time. It is important to note that whereas this study reports a novel approach for
subnormothermic kidney preservation with H2S-supplemented blood substitute, future ex
vivo perfusion studies using declined human kidneys and longer perfusion times are needed
to support our findings. Additionally, more in vitro research is required to establish the
exact mechanisms underlying the protective effects of AP39. Furthermore, research with
clinically approved H2S donors and in vivo models of renal transplantation is also needed
to facilitate the clinical translation of our novel approach.
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In conclusion, this study demonstrates that subnormothermic perfusion at 21 °C
with AP39-supplemented Hemopure improves ex vivo DCD porcine renal graft outcomes.
Our findings contribute to the expanding body of literature that supports the use of H2S and
subnormothermic preservation to improve kidney outcomes following transplantation.
Additionally, we have established a novel blood-free model of ex vivo kidney preservation
and reperfusion that will be useful for evaluating other therapeutics, such as other
gasotransmitters and gene therapies.
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Discussion and Conclusion
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5.1 Discussion
Renal transplantation is the preferred treatment for patients with end-stage kidney
disease.1 However, the ischemia-reperfusion injury (IRI) that occurs during organ
procurement and reimplantation limits renal graft longevity. Optimal organ preservation is
critical for mitigating IRI. Currently, cold/hypothermic temperatures (~4°C) are used for
preservation; however, this approach can exacerbate graft outcomes.2 Grafts that are
affected by severe IRI, such as those obtained from donors after cardiac death (DCD), are
being used more frequently to meet the rising demand for kidney transplants and these
organs are particularly susceptible to cold ischemic injury.3,4 In recent years, the body of
literature evaluating therapeutics and novel approaches that could improve renal graft
preservation has grown exponentially. Our group has previously shown that supplementing
cold preservation solutions with various hydrogen sulfide (H2S) donors, including AP39,
improves renal cell viability and in vivo kidney transplant outcomes.5,6 Additionally,
substantial research has shown that normothermic (36-37°C) and subnormothermic
preservation

(20-34°C)

improves

DCD

kidney

outcomes

compared

to

cold

preservation.7–9 In 2014, Hoyer et al. showed that oxygenated subnormothermic perfusion
of DCD porcine kidneys at 20°C improved outcomes compared to static cold storage on
ice and oxygenated hypothermic perfusion.10 The overarching aim of this thesis is to
evaluate the merit of subnormothermic preservation with H2S donor AP39. We
systematically used in vitro and ex vivo models of kidney preservation to demonstrate the
efficacy of subnormothermic preservation at 21°C with AP39 compared to static cold
storage, the clinical standard of care, and subnormothermic preservation without AP39. In
this chapter, we summarize and discuss our main findings and contextualize their
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importance in the fields of kidney preservation and H2S therapeutic research. Additionally,
potential mechanisms of action for AP39 during renal IRI, the strengths and limitations of
this thesis, and future directions for basic sciences and translational research are also
discussed.

5.1.1 Adding AP39 to preservation solutions, blood and blood
substitutes improves their suitability for subnormothermic
kidney preservation
A key finding of this thesis is that adding AP39 to preservation solutions, blood and
blood substitutes improves their suitability for subnormothermic kidney preservation. This
is remarkable considering the diverse compositions of these solutions. First, AP39 was
added to University of Wisconsin (UW) solution in our in vitro model (Chapter 2). UW
solution is an acellular solution that mimics intracellular ionic concentrations and contains
other compounds such as adenosine. Clinically, it is used for the cold preservation of livers,
kidneys, and pancreas.11 Adding AP39 to UW solution improved renal cell viability
following hypoxia at 10°C, 21°C and 37°C in a dose-dependent manner. Additionally,
DCD pig kidneys stored in UW+200 nM AP39 at 21°C exhibited lower necrosis than
kidneys stored on ice in UW solution alone. Thus, AP39 made UW solution, which was
designed to mitigate edema at 4°C, viable for subnormothermic preservation at 21°C. Next,
adding 200 nM AP39 to whole pig blood during subnormothermic perfusion at 21°C
improved DCD pig kidney outcomes (Chapter 3). Compared to an acellular solution like
UW solution, whole blood contains red blood cells and leukocytes. It is possible that H2S
may impact these cells in addition to the kidney,12 which might be contributing to the
improved outcomes of the treatment group (discussed in section 5.3). Furthermore, adding
200 nM AP39 to Hemopure during subnormothermic perfusion at 21°C also improved
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DCD pig kidney outcomes (Chapter 4). Hemopure is a hemoglobin-based oxygen carrier
that is used as a blood substitute. Like UW solution, Hemopure is an acellular solution as
it is composed of chemically stabilized, cross-linked bovine hemoglobin.13 Its oxygencarrying capacity rivals that of human blood14 and it eliminates the complexities associated
with acquiring human blood (global shortage) and using it for ex vivo kidney perfusion
(screening for pathogens, thrombosis, etc.). For these reasons, Hemopure is an ideal
perfusate for the clinical translation of oxygenated subnormothermic preservation. Overall,
the consistent improvement in renal outcomes observed after adding 200 nM AP39 to UW
solution, whole pig blood and Hemopure during subnormothermic preservation strengthens
the validity of our novel approach and our AP39 dose.
An important aspect to consider with all the experimental models used is the lack
of nutrients during the subnormothermic preservation period. Several studies on
normothermic kidney preservation have supplemented the perfusate with nutrients such as
glucose, amino acids, insulin, etc. in the form of drips.15 However, we chose not to do so
for two important reasons. Supplementing UW solution, pig blood and Hemopure with
only AP39 allowed us to evaluate the direct impact of the treatment on renal cell viability
and kidney outcomes during subnormothermic preservation without any confounding
variables. Additionally, the improvement of renal outcomes with AP39 treatment in the
absence of nutrients is advantageous for clinical translation. Current kidney preservation
methods, static cold storage on ice and hypothermic perfusion pumps, rely on the use of
acellular solutions and they do not have the capacity to provide nutrients continuously.11 If
we consider the path of least resistance towards clinical translation, the performance of
AP39-supplemented Hemopure at 21°C is optimal. In addition to being an acellular
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perfusate, AP39-supplemented Hemopure improves outcomes without the addition of
nutrients. Thus, implementing this approach clinically would only require modifications to
existing hypothermic perfusion pumps to allow temperature changes and oxygenation.
While these changes would require some innovation, this avenue is much more feasible
than trying to create a new apparatus that would allow temperature changes and support
nutrient drips without compromising on portability, which is critical for DCD organ
procurement.
One of the focal points of this thesis is the novel blood-free model of preservation
and reperfusion that was developed using Hemopure (Chapter 4). While Hemopure has
been used for normothermic and subnormothermic kidney preservation before,16,17 we are
the first to use it consecutively for subnormothermic preservation at 21°C and reperfusion
at 37°C. As discussed above, the efficacy of AP39-supplemented Hemopure is promising
because it allows us to circumvent the challenges associated with the use of blood for ex
vivo kidney preservation. During reperfusion, Hemopure was supplemented with a diuretic
(mannitol) along with dextrose and insulin drips to mimic the clinical post-transplant
milieu. Our use of supplements aligns with previous studies reviewed by Elliot et al.15 and
the consistent urine outputs observed within each group during reperfusion further supports
our novel protocol. Notably, perfusate lactate levels increased during reperfusion due to
the absence of hepatic metabolism to convert lactate to glucose and additional measures
would be needed to correct this finding in future studies. Nonetheless, our innovative
blood-free platform can be readily used for evaluating novel therapeutics and conducting
drug repositioning studies.
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Overall, the findings presented in this thesis show that adding AP39 to preservation
solutions, blood and blood substitutes improves their suitability for subnormothermic
kidney preservation. The consistent efficacy observed at the preservation temperature
(21°C) with the addition of 200 nM AP39 to these diverse solutions strengthens the validity
of our novel approach and our treatment dose. Additionally, AP39-supplemented
Hemopure is particularly suitable for the clinical translation of oxygenated
subnormothermic perfusion as it could be implemented with feasible changes to existing
kidney perfusion pumps since it is less viscous than blood. Furthermore, due to the
innovation needed to advance our research, we established a novel blood-free model of
preservation and reperfusion that will be useful for the evaluation of other therapeutics in
the context of kidney preservation.

5.1.2 Subnormothermic preservation with AP39 improves DCD renal
graft outcomes compared to static cold storage, the clinical
standard of care
The main finding of this thesis is that subnormothermic preservation with AP39
leads to improved or comparable outcomes relative to static cold storage, the clinical
standard of care. In this section, the results from each experimental model are discussed
sequentially to substantiate this conclusion. First, an in vitro model of renal IRI was used
to evaluate the efficacy of AP39-supplemented UW solution during cold (10°C),
subnormothermic (21°C), and normothermic (37°C) preservation (Chapter 2).
Supplementing UW solution with AP39 increased renal cell viability in a concentrationdependent manner at each temperature. Since UW solution was designed for cold
preservation, the highest renal cell viability was observed following cold preservation and
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the lowest renal cell viability was observed following normothermic preservation.
However, when outcomes following cold and subnormothermic preservation were
compared, it was found that supplementing UW solution with AP39 reduced the gap in
renal cell viability between the two conditions in a concentration-dependent manner. This
led to the ex vivo model where DCD pig kidneys were treated to 24h of static cold storage
on ice (4°C) in UW solution or static subnormothermic storage (21°C) in UW solution with
or without AP39. Importantly, static subnormothermic storage in UW + 200 nM AP39
significantly reduced tissue necrosis compared to static cold storage. However, 4h of this
approach followed by 4h of ex vivo reperfusion using autologous pig blood (unpublished,
model from Chapter 3) led to a drastic reduction in oxygenation and darkening of the
kidneys was observed (indicative of thrombosis). By this point, our focus had shifted
towards evaluating AP39 in perfusion models (Chapters 3 and 4) since oxygenated
perfusion is the norm in the literature on alternatives to cold preservation. However, the
findings mentioned above may have been a result of the intracellular-type ion composition
of UW solution rather than the approach of using AP39-supplemented preservation
solution for static subnormothermic storage. Several studies have reported that
extracellular-type solutions are more effective for static subnormothermic storage (2223°C) of kidney grafts than UW solution.18,19 Thus, future research investigating the effects
of supplementing extracellular-type solutions with H2S could be useful for establishing a
static subnormothermic storage protocol for kidney grafts.
While static subnormothermic storage would be easier to translate to clinical
practice than subnormothermic perfusion, it would not address the increase in metabolic
demand that occurs within the kidney at 21°C compared to 4°C. This rise in metabolic
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demand is a primary factor underlying the use of oxygenated perfusion by researchers who
are investigating novel kidney preservation protocols to replace cold storage. Most of the
research conducted in this regard is focused on normothermic perfusion (37°C), which has
been shown to improve renal graft outcomes when used after cold preservation or in place
of it.8,20 The emergence of subnormothermic preservation is more convoluted. In the early
2000s, a group based in the Netherlands showed that a period of perfusion at 32-34°C with
metabolic support following prolonged static cold storage improved the outcomes of pig
and declined human kidneys.9,21,22 This approach was never directly compared to cold
storage and the research was later abandoned. In 2014, two independent studies reported
that perfusing pig kidneys and declined human livers with acellular solutions at 20-21°C
improved graft outcomes.10,23 Around this time, temperatures below normothermic (3637°C) levels were referred to as ‘subnormothermic’; however, the lower boundary of this
range was unknown. A few years later, our centre compared the effect of perfusing DCD
pig kidneys with autologous blood at 15°C, 22°C and 37°C to static cold storage.24 It was
found that subnormothermic perfusion at 22°C improved urine output and reduced tissue
injury compared to static cold storage and normothermic preservation. While this research
was published in 2019, the preliminary findings of that study along with our in vitro
findings (Chapter 2) shaped the ex vivo models used to evaluate AP39 (Chapters 3 and 4).
Additionally, the thrombosis observed during kidney perfusion at 15°C suggests that this
temperature may be too low for blood-based oxygenated perfusion. Based on the evidence
summarized above, temperatures in the range of 20-34°C are referred to as
‘subnormothermic’ in this thesis. However, it is possible that acellular solutions may be
effective for oxygenated kidney perfusion at temperatures below 20°C since acellular

168

solutions have been used for oxygenated cold preservation at 4°C.10 Although the
‘subnormothermic’ designation is somewhat arbitrary since certain temperatures have not
been tested, it is clear that preservation at 20-23°C improves renal outcomes compared to
cold storage.
Considering the complex milieu described above, it is remarkable that
subnormothermic preservation with 200nM AP39 at 21°C improved renal graft outcomes
relative to static cold storage in both of our ex vivo kidney perfusion models (Chapters 3
and 4). The most important outcome to consider is urine output. Perfusing DCD pig
kidneys with AP39-supplemented blood and AP39-supplemented Hemopure at 21°C
significantly improved urine output compared to static cold storage, the clinical standard
of care. The immediacy of post-operative urine output is an important kidney transplant
outcome as it determines whether dialysis is needed to address delayed graft function. In
2018, Hosgood et al. successfully transplanted declined human kidneys after assessing
several parameters, including urine output, during 1h of ex vivo normothermic perfusion.25
The five kidneys that were transplanted based on the study’s criteria had higher urine
outputs than those that were not transplanted (based on clinical findings, suboptimal
biopsies and poor HMP parameters) and only one kidney exhibited delayed graft function.
Although additional research is needed to validate their method, their findings suggest that
ex vivo urine output can be used to determine if a kidney is suitable for transplant. While
our novel preservation approach has not been evaluated using declined human kidneys, the
difference in urine output observed in this study has promising implications.
Beyond urine output, kidneys perfused with AP39-supplemented blood at 21°C
exhibited lower levels of apoptosis, similar levels of acute tubular necrosis and pro-survival
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gene expression patterns compared to the kidneys treated with static cold storage (Chapter
3). Furthermore, kidneys perfused with Hemopure+200 nM AP39 at 21°C exhibited lower
levels of apoptosis and similar levels of acute tubular necrosis compared to kidneys treated
with static cold storage (Chapter 4). These findings match the results of our previous study
comparing DCD pig kidney outcomes after static cold storage or subnormothermic
preservation with Hemopure or blood.16 The Hemopure+200 nM AP39 group also
displayed higher tissue oxygenation and perfusate pO2 levels along with lower urine protein
levels compared to the static cold storage group (statistically comparable). Importantly, the
poorer outcomes of the Hemopure+1µM group compared to both of these groups further
substantiates the use of 200 nM AP39 in future studies.
Overall, the findings presented in this thesis show that subnormothermic kidney
preservation with AP39 leads to improved or comparable outcomes relative to static cold
storage, the clinical standard of care. Although more research is needed to substantiate our
novel approach, the consistent efficacy of our novel approach in all of the porcine models
used demonstrates its strong clinical potential. Subnormothermic preservation at 21°C is
likely effective because it avoids the damage caused by cold storage while providing a
phase of lower metabolic demand than normothermic preservation. Additionally,
supplementing perfusion solutions with AP39 mitigates some of the negative effects of the
higher metabolic demand that occurs at 21°C compared to 4°C (discussed in section 5.3).
Thus, subnormothermic preservation at 21°C with exogenous H2S therapy is a promising
alternative to cold storage for optimal kidney preservation.
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5.1.3 Subnormothermic preservation with AP39 reduces renal
apoptosis and induces pro-survival gene expression
Our results consistently show that subnormothermic preservation with AP39
reduces apoptosis compared to subnormothermic preservation without AP39 and static
cold storage. In our in vitro model of renal IRI (Chapter 2), treatment with AP39supplemented UW solution reduced renal cell apoptosis during subnormothermic storage
compared to UW solution. In both the ex vivo models (Chapters 3 and 4), subnormothermic
perfusion with AP39-supplemented blood and AP39-supplemented Hemopure reduced
apoptosis compared to subnormothermic perfusion without AP39 and static cold storage,
the clinical standard of care. These results align with previous studies that have investigated
the effect of AP39 on renal injury. Ahmad et. al, have previously shown that pretreatment
of rats with AP39 reduced apoptosis caused by acute warm renal IRI (37°C) resulting from
30 min of renal vascular clamping followed by 6h of reperfusion.26 Additionally, our group
has previously shown that cold preservation (12°C) of renal epithelial cells with AP39supplemented UW solution increased cell viability and reduced apoptosis compared to
preservation with UW solution alone.6 While previous studies have reported that AP39
exerts an anti-apoptotic effect during cold and normothermic renal IRI, we are the first to
report that this also occurs during subnormothermic kidney preservation at 21°C.
The mechanism(s) underlying the reduction in apoptosis following AP39
administration have not been fully elucidated. However, several studies have suggested
potential targets. Using an in vitro model of cold myocardial IRI, our collaborators have
reported that AP39 downregulated BAX, a pro-apoptotic factor, at the protein and mRNA
level.27 Vitvitsky et. al have shown that the reduction of cytochrome c, an initiator of
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apoptosis, by H2S donors (including AP39) was critical for potentiating sulfide signaling
through persulfidation, which diminished the pro-apoptotic activity of caspase 9.28 Our
RNAseq results (Chapter 3) showed that subnormothermic perfusion of DCD pig kidneys
with AP39-supplemented blood downregulated transcriptional regulators of the intrinsic
apoptotic pathway, BCL10,29,30 and endoplasmic reticulum stress-induced apoptosis
pathway, DDIT3,31 compared to static cold storage. While more research is needed to
confirm the exact mechanism(s) underlying the anti-apoptotic effects of AP39, the
implication of BAX, cytochrome c and BCL10 suggests that the intrinsic apoptotic
pathway might be a key target.
Although the direct impact of AP39 on apoptosis is of primary interest, it is
important to consider indirect targets that may be contributing to the observed reduction in
apoptosis. Due to its mitochondria-targeted nature, AP39 modulates mitochondrial
processes that may contribute to reducing apoptosis. Our group has previously shown that
cold preservation (12°C) of renal epithelial cells with AP39-supplemented UW solution
preserved mitochondrial membrane potential and reduced ROS production compared to
preservation with UW solution alone.6 The same trends were observed by Nishime et al.
who evaluated mitochondrial membrane potential and ROS production in islet cells
isolated from porcine pancreas that were preserved in cold AP39-supplemented UW
solution.32 Mitochondrial membrane potential is critical for regulating the opening of the
mitochondrial permeability transition pore (MPTP), which leads to the release of proapoptotic factors, such as cytochrome c, that potentiate apoptosis by engaging caspases.33
It is unknown whether AP39 modulates MPTP opening in renal IRI. However, Karwi et al.
have shown that AP39 inhibited MPTP opening in rat hearts following myocardial IRI.34
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It is likely that this occurs independent of Cyclophilin-D, a modulator of the MPTP, as
AP39 has been shown to increase mitochondrial Ca2+ retention, which discourages MPTP
opening, and reduce cardiac infarct size in mice lacking Cyclophilin-D.35 The effects of
AP39 on the targets and processes discussed above are summarized in Fig. 5-1. Evidently,
the effects of AP39 on mitochondrial bioenergetics need to be studied further to fully
elucidate the mechanisms underlying its protective effects, especially in renal IRI.

Figure 5-1 A summary of the various mitochondrial targets and cellular processes
that AP39 modulates to reduce apoptosis. During IRI, ROS generation and accumulation
of Ca2+ in the mitochondria leads to the opening of the MPTP and the release of cytochrome
c, which leads to the initiation of apoptosis. AP39 has been shown to exert diverse effects
that have anti-apoptotic consequences including reducing ROS generation, increasing Ca2+
retention, inhibiting MPTP opening, downregulating BAX and reducing cytochrome c,
which limits apoptosis through potentiating sulfide signaling.
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In addition to reducing apoptosis, our RNAseq results (Chapter 3) showed that
subnormothermic perfusion of DCD pig kidneys with AP39-supplemented blood (SNTAP)
induced other pro-survival gene expression patterns. Compared to subnormothermic
perfusion with blood alone (SNT), several genes associated with the HIF1α-mediated
hypoxia response, which contributes to acute kidney injury and renal IRI,36 were
downregulated in the SNTAP group. The downregulated genes include metabolic targets
of HIF1α, PCK-1 and PDK3,37,38 and negative regulators of HIF1α-mediated angiogenesis,
EGR1 and RGCC,39,40 that may help with managing metabolic demand at 21°C and
promoting vascularization respectively. While no previous studies have linked AP39 to the
HIF1α-mediated hypoxia response, other H2S donors have been shown to improve
outcomes in hypoxic conditions through modulating the activation of the HIF1α
pathway.41,42 If confirmed by future research, these mechanisms could explain why AP39
is so effective in various models of hypoxic/ischemic injury.
Importantly, IL6 was downregulated in the SNTAP group compared to the SNT
group. This finding is supported by the reduction/downregulation of IL6 observed after
AP39 treatment in the context of cold myocardial IRI, burn injury and airway
hyperreactivity.27,43,44 Since IL6 is known to play a critical role in various forms of IRI,
including renal IRI and acute kidney injury,45 investigating the effect of AP39 on IL6 and
its downstream targets more directly could be useful to establish the anti-inflammatory
effects of AP39. Our RNAseq results also showed the upregulation of MAPK7, a
proliferation gene, and NRROS, a negative regulator of ROS production, in the SNTAP
group relative to the other groups.46,47 If confirmed by future mechanistic analyses, these
genes and the pathways associated with them could explain the enhanced cell viability and
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reduced ROS production reported by several previous studies on AP396,27,32 and our in
vitro results (Chapter 2).
Since we are the first to investigate the use of AP39 in subnormothermic kidney
preservation, substantial future research is needed to establish the exact mechanisms
underlying the protective effects of AP39 observed in this context. Three distinct avenues
for future research emerge from our findings, namely the effect of AP39 on the intrinsic
apoptotic pathway, the HIF1α-mediated hypoxia response and IL6-mediated inflammation.
Several methods can be used to evaluate the mechanistic effects of AP39 in the context of
subnormothermic preservation. The primary approach would be to genetically knockdown
some of the targets identified above, such as BAX or IL6, in a human kidney cell line and
evaluate the effect of AP39 treatment on cell viability following hypoxia at 21°C and
reoxygenation at 37°C using an in vitro model similar to the one used in Chapter 2. Once
a target contributing to AP39’s protective effects is identified, cellular pathways involving
that target would need to be investigated further and the mechanistic findings would need
to be confirmed in tissues from an in vivo model of kidney transplantation.
Overall, the findings presented in this thesis show that subnormothermic
preservation with AP39 reduces apoptosis and induces pro-survival gene expression. Only
a handful of previous studies on the biological applications of AP39 are relevant to the
discussion of our results and parallels have been drawn to substantiate our results wherever
possible. It is important to note that most of these studies discussed in this section report
effective doses in the range of 100 - 400 nM AP396,27,28,32,44 and our dose, 200 nM AP39,
falls within that range. In addition to comparing our results to the results of previous
studies, the novel implications of our RNAseq data have also been highlighted above.
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5.2 Strengths and Limitations
The conclusions presented in this thesis are strengthened by several facets of the
experimental approaches that we used. The premise of this work revolves on developing
an alternative to cold preservation to mitigate the renal graft injury it causes, particularly
for DCD kidneys. Therefore, the induction of warm ischemic injury to mimic DCD
conditions was a critical factor in developing relevant models. In all three porcine models
used (Chapters 2, 3 and 4), the renal pedicle was clamped for 30 or 60 minutes to induce
a complete cessation of blood flow. This induces more significant injury than the gradual
cessation of blood flow that occurs in a clinical setting as the donor experiences cardiac
death. Thus, the results of this study would likely be enhanced in the clinical setting since
our approach led to urine output despite the induction of more severe kidney injury.
Additionally, the use of 21°C as the ideal temperature for subnormothermic preservation
is validated through comparisons with cold (4-10°C) and normothermic (37°C)
temperatures in our in vitro model (Chapter 2) and our ex vivo porcine kidney perfusion
model.24 Furthermore, the use of 200 nM AP39 is supported by the improved outcomes
observed for this treatment group in all three porcine models relative to the static cold
storage group (Chapters 2, 3 and 4) and a treatment group that received a 5x higher dose
of AP39 (Chapter 4). Over time, our novel approach has been optimized sequentially by
working through the stages of in vitro research before moving on to using several models
of static and dynamic ex vivo kidney preservation. Through this process, several major
challenges have been overcome, such as the shortage of blood, to transform a novel idea
into a viable kidney preservation approach that is effective in pre-clinical models and is
pending patent approval.
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In order to fully contextualize the findings of this thesis, however, it is important to
examine the limitations in addition to considering the strengths. The ex vivo porcine kidney
perfusion models used to evaluate the efficacy of supplementing blood and Hemopure with
AP39 (Chapters 3 and 4) were appropriate considering the novelty of our approach.
However, the preservation and reperfusion periods (4h each) were relatively short and the
availability of a single pulsatile pump for treating pairs of organs limited the individual
analysis of each porcine kidney. Although these limitations somewhat weakened our
findings, they facilitated the execution of the vast number of porcine experiments required
for this thesis with limited manpower as one person was able to monitor a single pump for
the duration of preservation and reperfusion (8h). Despite the clinical relevance of our ex
vivo porcine kidney perfusion models, evaluating our novel approach using declined
human kidneys would have been more indicative of clinical outcomes. Unfortunately, this
avenue was limited due to the drop in organ procurement and transplantation during the
COVID-19 pandemic. Furthermore, the lack of an in vivo transplantation model made it
difficult to determine the effects of our novel approach on recipient survival and posttransplant outcomes. While an attempt was made to establish a porcine kidney
transplantation model, its success was limited by veterinary challenges and a lack of
manpower. Additionally, while my in vitro and RNAseq data (Chapters 2 and 3) show the
anti-apoptotic and other pro-survival effects of AP39 during subnormothermic
preservation, more research is needed to confirm the cellular mechanisms at play.
Furthermore, in order to fully understand how AP39 works, the challenges associated with
the detecting and quantifying the levels and effects of H2S (due to its transient nature) need
to be overcome, especially in the context of physiological systems.
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5.3 Future Directions
Based on the limitations identified above, three clear paths for future research
emerge. First, evaluating the effect of ex vivo subnormothermic perfusion with AP39 on
declined human kidneys, with donor blood and/or Hemopure, would provide invaluable
insight on the clinical outcomes of our novel approach. Next, the use of an in vivo porcine
transplantation model as previously described in the literature20 would help to establish the
safety of our novel approach by evaluating its effect on recipient survival and posttransplant outcomes. In addition, the cellular mechanisms underlying the protective effects
of AP39 need to be studied further. Potential targets known to be modulated by AP39
(apoptosis, inflammatory and/or hypoxia response genes) can be knocked down in human
kidney cell lines. These cell lines can then be subjected to hypoxia/reoxygenation to mimic
renal ischemia-reperfusion injury, with and without AP39 treatment, to determine whether
AP39 mitigates the adverse effects of the absence of specific target genes that impact renal
cell viability. Additionally, RNAseq or microarray analysis could be conducted on declined
human kidneys treated with subnormothermic perfusion with AP39-supplemented blood
or Hemopure to further confirm the mechanisms elucidated through in vitro research.
While the three avenues listed above are essential for advancing the findings of this
thesis, several additional directions for future research may be of interest. The novel ex
vivo model of blood-free preservation and reperfusion established in this thesis may be
useful for drug repositioning studies to evaluate other therapeutics that may improve
kidney graft preservation. Future research could also address the downside of using AP39,
which is that it has not been approved for clinical use yet. Evaluating a clinically approved
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H2S donor, such as sodium thiosulfate, using the models described above may be more
advantageous to facilitate the clinical translation of subnormothermic preservation with
H2S. Research conducted by our lab (unpublished) shows that supplementing cold
preservation solutions with sodium thiosulfate improves renal graft outcomes in a rat model
of renal transplantation. These results have also translated to a pilot renal transplantation
clinical trial being conducted at our centre. Another factor limiting the translation of
subnormothermic preservation with H2S is the lack of portable perfusion devices that allow
deviation from cold preservation and support perfusates such as blood or Hemopure. One
of our collaborators is working with an industry partner to modify an existing portable
perfusion device so that it can support oxygenated subnormothermic perfusion with
Hemopure. If such a setup was approved for clinical use after it has been tested using
porcine and human kidney grafts, a major barrier to the clinical translation of our approach
would be eliminated. Although these changes require a significant financial investment and
technical expertise, the possibility of using discarded and marginal kidney grafts to save
more lives warrants the undertaking of these efforts. Overall, the research conducted by
our group and others is rapidly advancing the clinical translation of subnormothermic
kidney preservation and the use of H2S donors in this context.

5.4 Conclusion
The overarching aim of this thesis is to evaluate the merit of subnormothermic
kidney preservation at 21°C with H2S donor AP39. Our results showed that adding AP39
to preservation solutions, blood and blood substitutes improved their suitability for
subnormothermic kidney preservation. Importantly, we found that subnormothermic
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preservation with AP39 improved DCD renal graft outcomes compared to static cold
storage, the clinical standard of care. Furthermore, subnormothermic preservation with
AP39 reduced renal apoptosis and induced pro-survival gene expression. Through the
sequential use of cutting edge kidney preservation models, we transformed a novel yet
obscure idea into a viable and effective kidney preservation approach that is pending patent
approval (US patent application serial no. 17/127,965). Additional research and innovation
are needed to facilitate the clinical implementation of subnormothermic kidney
preservation at 21°C with H2S. Nonetheless, the experimental models and findings
presented in this thesis will inform future studies seeking to evaluate novel kidney
preservation approaches and advance the clinical use of H2S therapeutics.
Notably, renal blood flow was stopped completely rather than gradually in our
porcine models, which induced more severe warm ischemic injury than the clinical DCD
scenario. Thus, the positive impact of subnormothermic preservation with AP39 would
likely be enhanced upon clinical translation. While additional research with declined
human kidneys and clinically approved H2S donors is essential for advancing this research,
subnormothermic preservation with H2S shows the potential to enhance the outcomes of
marginal kidney grafts from deceased donors with significant warm ischemic injury. Thus,
the most important implication of this research is its potential to expand the pool of
transplantable kidneys.
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6.3 Copyright Release for Chapter 3 and 4
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6.4

Animal Ethics Approval

AUP Number: 2018-090
PI Name: Sener, Alp
AUP Title: Evaluating Subnormothermic Organ Preservation
With Hydrogen Sulfide As A Method To Improve Injured Renal
Graft Viability.
Official Notification of ACC Approval: Animal Use Protocol 2018090 has been approved.
Please at this time review your AUP with your research team to ensure
full understanding by everyone listed within this AUP.
As per your declaration within this approved AUP, you are obligated to
ensure that:
1) Animals used in this research project will be cared for in
alignment with:
a) Western's Senate MAPPs 7.12, 7.10, and
7.15 http://www.uwo.ca/univsec/policies_procedures/research.html
b) University Council on Animal Care Policies
and related Animal Care Committee procedures
c)
http://uwo.ca/research/services/animalethics/animal_care_and_use_p
olicies.htm
2) As per UCAC's Animal Use Protocols Policy,
a) this AUP accurately represents intended
animal use;
b) external approvals associated with this AUP,
including permits and scientific/departmental peer approvals, are
complete and accurate;
c) any divergence from this AUP will not be
undertaken until the related Protocol Modification is approved by the
ACC; and
d) AUP form submissions - Annual Protocol
Renewals and Full AUP Renewals - will be submitted and attended to
within timeframes outlined by the
ACC.http://uwo.ca/research/services/animalethics/animal_use_protoc
ols.html
3) As per MAPP 7.10 all individuals listed within this AUP as having
any hands-on animal contact will
a) be made familiar with and have direct
access to this AUP;
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b) complete all required CCAC mandatory
training (training@uwo.ca ); and
c) be overseen by me to ensure appropriate
care and use of animals.
4) As per MAPP 7.15,
a) Practice will align with approved AUP
elements;
b) Unrestricted access to all animal areas will
be given to ACVS Veterinarians and ACC Leaders;
c) UCAC policies and related ACC procedures
will be followed, including but not limited to:
i) Research Animal
Procurement
ii) Animal Care and Use
Records
iii) Sick Animal Response
iv) Continuing Care Visits
5) As per institutional OH&S policies, all individuals listed within
this AUP who will be using or potentially exposed to hazardous
materials will have completed in advance
the appropriate institutional OH&S training, facility-level training,
and reviewed related (M)SDS Sheets,
http://www.uwo.ca/hr/learning/required/index.html
Submitted by: Copeman, Laura
on behalf of the Animal Care Committee
University Council on Animal Care
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